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A STUDY ON   SECONDARY   BACTERIAL INFECTIONS 
ASSOCIATED WITH DERMATOLOGICAL LESIONS AND 
THEIR ANTIMICROBIAL SUSCEPTIBILITY PATTERN  IN 
A TERTIARY CARE HOSPITAL 
ABSTRACT 
INTRODUCTION:    
Skin and soft-tissue infection   is defined as  an  inflammatory microbial invasion 
of the epidermis, dermis and subcutaneous tissues. One common etiology of  skin and 
soft tissue infection is the secondary  bacterial infection that complicates the skin lesions. 
The   dose,  route and duration of the antimicrobial treatment in these patients  are   
predicated with the  knowledge of the potential pathogens with their antimicrobial 
sensitivity . 
This study was conducted at the Institute of Microbiology ,Madras Medical 
college, Chennai , to isolate the pathogens  from  patients  with  secondarily infected skin 
lesions (Psoriasis, Atopic dermatitis, Pemphigus lesions  and Leprosy with infected ulcer) 
from various sites and to determine their antimicrobial susceptibility pattern . 
MATERIALS &METHODS: 
200 patients (≥18 yrs) with signs and symptoms of secondary infection of skin 
lesions attending the department of  Dermatolgy , Rajiv Gandhi Government General 
Hospital, Chennai were included in the study. Pus and blood samples were collected from 
these patients and processed by   standard  microbiological techniques. 
RESULT:  
Out of 200 samples 63 , 62,52 and 23 samples were taken respectively  from 
Atopic Dermatitis/Eczema, Pemphigus, Psoriasis and Leprosy with infected ulcer 
,including 114 inpatiens and 86 outpatients.88% of samples were positive for culture. 
Aerobic  gram positive organisms accounts for 59.9% followed by aerobic gram negative 
37.27% and anaerobic organisms 2.83%. In Atopic Dermatitis/Eczema 57.7% of isolates 
were Staphylococcus aureus followed by Streptococcus pyogenes, Enterobacteriacea and 
anaerobic organisms. 
Most common isolate in Psoriasis was Staphylococcus aureus (64%) followed by 
Enteric gram negative bacilli and Staphylococcus epidermidis. 
Pseudomonas aeroginosa (48%) was the most common organism in leprosy with 
infected ulcer followed by Proteus vulgaris(22%). 
Blood culture from17 In patients, [11 from Pemphigus(1.77%) and 6 from 
Psoriasis(1.15%)] resulted in MRSA isolation from two cases of Pemphigus. 
ESBL producers were 62.5%. All the ESBL   producers  were sensitive to 
Imipenem. 
 64%Staphylococcus aureus   were MSSA and 36% were MRSA. All MRSA were 
positive for mec A  gene .MRSA from OP patients(CA MRSA) showed higher positivity 
for Pvl gene 90%    and  22% of MRSA from IP patients(HA MRSA) were positive for 
Pvl gene. All the  Methicillin resistant  Staphylococcus aureus were sensitive to 
vancomycin. 
CONCLUSION:  
MRSA with higher rate of resistance to many routinely used antibiotics  and  
Enterobacteriaceae   with higher levels of ESBL production were isolated. Hence 
bacterial culture and sensitivity of specimens from the secondarily infected skin lesions 
should be performed to confirm the bacterial etiology and  to initiate effective  antibiotic 
treatment so as to decrease the morbidity and mortality of these patients, that  also limits 
the misuse of antimicrobials which would  prevent the emergence of resistant bacterial 
strains in the hospital and  the community. 
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INTRODUCTION 
Skin diseases are most common affecting   up to 20 to 30 % of 
individuals at a particular time in the general population 
[4]
.  Skin and 
soft-tissue infection   is defined as  an  inflammatory microbial invasion 
of the epidermis, dermis and subcutaneous tissues
[2]
. One common 
etiology of skin and soft tissue infection is the secondary bacterial 
infection that complicates the skin lesions
[3]
. 
Chronic skin diseases include common    inflammatory dermatoses 
like atopic dermatitis and psoriasis with peak incidences in childhood and 
young adulthood, and   the extensive bullous diseases including bullous 
pemphigoid and leg ulcers with peak incidence among adults 
[5]
. Skin 
lesions that are complicated by secondary bacterial invasion is broadly 
classified into two classes. First class includes the itchy skin conditions in 
which scratching provides a portal of entry to microorganisms and the 
other class are  those that are  characterized by the absence of skin 
barrier, like eczema, pemphigus and ulcers.
[6] 
Human   skin   by acting as  a    physical     barrier, secreting low 
pH   sebaceous fluid and fatty acids functions as a  first line of defence 
against micro organisms. It also has  the   normal flora mainly bacterial, 
which decreases the colonization by  pathogenic organisms . An intact 
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stratum corneum prevents invasion of skin by normal skin flora or 
pathogenic microorganisms
[1]
. These barriers are lost  most commonly in 
the Skin and soft-tissue infections( SSTIs).  
The normal healthy skin surface is colonized by many bacterial 
species like Staphylococcus aureus, diphtheroids and coagulase negative 
staphyloccocci which under normal conditions do not lead to cutaneous 
infections. But, when the skin barrier function is disturbed by a chronic 
skin disease there will be a massive   microbial colonization that   
subsequently  leads to clinically apparent cutaneous infection
[4]
. 
Staphylococcus aureus accounts for 30-50% of skin and soft tissue 
infections, followed by the enterobacteriaeceae, non-fermenters, beta-
hemolytic Group A streptococci  and anaerobes. There is also a high risk 
of colonization with Staphylococcus aureus and cutaneous infections 
among patients with chronic skin lesions like atopic dermatitis, psoriasis. 
Staphylococcus aureus are found in 60% of psoriasis patients,  and 88% 
of atopic dermatitis patients
[8]
. On an average more than 90% of 
community acquired strains of Staphylococcus aureus elaborate 
penicillinases or beta-lactamases   and 20-30% of Staphylococcus aureus 
are methicillin resistant. The prevalence of MRSA in India   also  shows a  
rise  in trend and there are reports of  MRSA in the community-acquired 
infections also though the prevalence is much lesser. MRSA  strains also 
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shows a high degree of resistance to other antibiotics especially, 
erythromycin and aminoglycosides 
[16]
. 
Hence   patients with chronic skin diseases may have an increased 
risk of more severe cutaneous   infections,    and needs prolonged period 
of antibiotic treatment. These infections may lead to serious local and 
systemic complications which progress rapidly and could   be   potentially 
life- threatening . 
The   dose  route and duration of the antimicrobial treatment   is 
predicated with the  knowledge of the potential pathogens with their 
antimicrobial sensitivity , disease severity and clinical complications. 
Hence the recognition of the resistance of these organisms can help in  
guiding  appropriate selection of antibiotic therapy. 
This cross sectional   study was done  to isolate the bacteria from  
patients  attending the dermatology department of Rajiv Gandhi 
Government General Hospital  with various secondarily infected skin 
lesions (Psoriasis, Atopic dermatitis, Pemphigus lesions  and Leprosy 
with infected ulcer) from various sites and to determine their 
antimicrobial susceptibility pattern so as to initiate effective antibiotic 
therapy thereby decreasing the morbidity and mortality of the patients. 
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AIMS AND OBJECTIVES 
1. To isolate the bacteria associated with dermatological lesions and to 
determine their antimicrobial susceptibility pattern. 
2. To study the bacteriological profile of various chronic skin lesions 
(Atopic dermatitis/Eczema, Psoriasis, Pemphigus, Leprosy with 
infected ulcer). 
3. To study the isolation of pathogens  from various anatomical sites. 
4. To determine the antimicrobial resistance pattern of the most 
commonly isolated organism by   phenotypic and genotypic 
methods. 
5. To evolve an antibiotic policy for the management of these 
infections. 
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REVIEW OF LITERATURE 
The firm knowledge that bacteria were the causative and 
transmitting  agent of disease and were responsible for contagion was 
acquired in the 19
th
 century, but the idea that there were tiny creatures 
that could produce illness has been held for thousands of years. The ideas 
of infection were recorded by Hippocrates in 300BC and proposed in his 
classic tome “De Contagione” that “seeds of contagion” might be 
responsible for infection
[9]
. 
PREVALENCE OF SECONDARY BACTERIAL INFECTION IN 
CHRONIC SKIN LESIONS: 
Secondary bacterial infections are common complications of 
primary dermatoses like Dermatitis/Eczema, Psoriasis, Pemphigus, 
chronic ulcers of Leprosy. Prevalence of infection varies between the 
lesions.  Infection is most commonly caused by mixed bacterial flora 
whose origin is endogenous oral, gastrointestinal or skin 
[10, 11]
. 
Colonization means that the bacteria grow and multiply on the nutrient 
surface of the skin without clinical apparent infection, and infection 
means that multiplication within the skin leading to clinical apparent 
infection within the skin or deeper. Staphylococcus aureus was found in 
60% of psoriasis patients, 88% of atopic dermatitis patients
[4]
. In 
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pemphigus the most common isolates are Staphylococcus aureus  which 
accounts for 68% of infection followed by Enterobacteriaceae  
[13]
.In 
leprosy with infected ulcers the most common isolates were 
Pseudomonas and Proteus followed by Staphylococcus
[14,15]
. 
NORMAL CUTANEOUS FLORA 
The organisms that survives and multiply in various ecologic 
niches of skin constitutes the “normal cuaneous flora”.Normal skin flora 
can be classified into the following types
[17]
. 
Resident Flora:- 
These organisms grow on the skin and are relatively stable in 
number and composition at a particular site and are attached to the skin. 
The increase in their number results from their multiplication and not due 
to addition of bacteria from outside. 
Transient Flora:- 
These organisms lies free on the skin without attachment and they 
are derived from exogenous sources. They are unable to multiply on the 
skin and vary both in type and number and disappear from skin with in a 
short time. 
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Temporary Residents/ transient Residents:- 
These organisms can colonize the skin of a small percentage of 
subjects in a modest number for a little longer time
[18]
. 
PROTECTIVE MECHANISMS OF SKIN TO INFECTION:- 
Intact skin acts as a physical barrier between the host, and the 
external world, preventing most pathogens from harming the host. The 
epidermis impedes penetration of microbial organisms, chemical irritants 
and toxins; absorbs and blocks solar and ionized radiation; and inhibits 
water loss. 
The relative dryness of normal skin specifically contributes to the 
marked limitation of growth of bacteria; especially Gram negative bacilli. 
Humans have fewer bacteria on exposed parts such as hand and forearms 
than axilla
[19]
. 
Both innate immunity and adaptive immunity in skin are involved 
in protecting skin from invading organisms
[20]
. 
The innate immune system:- 
 Innate immune system of skin relies on a series of "pattern 
recognition receptors" that recognize "pathogen-associated 
molecular patterns" that are not present on self. Binding of the 
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pattern recognition receptors to the pathogen-associated molecular 
patterns results in opsonization and activation of the complement 
system as well as induction of inflammatory signaling pathways. 
This process involves at least three pattern recognition receptors: (1) 
antimicrobial peptides (2) Toll-like receptors (TLRS), and (3) the 
complement system. All these three systems engage bacteria once 
they enter the skin and by  signaling, bring neutrophils and other 
immune cells to the site of infection to destroy the pathogen
[19,20]
. 
Antimicrobial peptides :- 
 Expressed on the skin surface as well as in eccrine sweat and saliva. 
 Produced by activated keratinocytes and are delivered to the skin 
surface in the lamellar bodies. Their appearance on the skin surface 
is closely tied to the production of normal skin stratum corneum 
lipids. 
 These small proteins have a characteristic physical property, the 
presence of an amphipathic organization, with one portion being 
cationic and capable of binding to microbial membranes, and another 
being hydrophobic allowing for insertion into bacterial lipid 
membrane. The insertion into the membrane results in membrane 
disruption and microbial death. A second principle of anti microbial 
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peptides is that they are processed after release by enzymes on the 
skin surface, resulting in multiple peptides each with different 
activities and different targets. The third principle of antimicrobial 
peptides is that they are also potent activators of the host immune 
response. The two antimicrobial peptides studied to date on the skin 
are the cathelicidines (LL-37) and the β-defensins. 
Cathelicidines:- 
 Peptides with a structurally variable antimicrobial domain at the C-
terminus. 
 Humans possess only one type of cathelicidine gene. The human 
precursor protein hCAP 18 (human cathelicidine antimicrobial 
protein 18) is produced by skin cells, including keratinocytes, mast 
cells, neutrophils, and ductal cells of eccrine glands. 
 Neutrophil proteases (proteinase 3) process hCAP18 into effector 
molecule LL-37, which has antibacterial, antiviral and antifungal 
properties. LL-37 further contributes to innate immunity by 
attracting mast cells and neutrophils via formyl peptide receptor and 
by inducing mediator release from latter cells via a G protein-
dependent, immunoglobulin E independent mechanism. It has now 
been shown that LL-37 is secreted into human sweat, where it is 
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cleaved by a serine protease-dependent mechanism into its peptides 
RK-31 or KS-30, which display an even more potent antimicrobial 
activity than intact LL-37. 
β-Defensins 
Cysteine-rich cationic low-molecular-weight antimicrobial 
peptides. 
Three types (HBD-1, HBD-2 and HBD-3) of β -defensins were 
isolated. 
HBD-1 is constitutively expressed on epidermis and has 
antimicrobial activity against Gram negative bacteria and appears to play 
a role in keratinocyte differentiation. 
 HBD-2 is inducible by microbes, including Pseudomonas 
aeruginosa, Staphylococcus aureus and Candida albicans, and also by 
pro-inflammatory cytokines such as tumor necrosis factor-α and 
interleukin-1. It has antimicrobial activity against Gram-negative bacteria 
such as Escherichia coli and Pseudomonas aeruginosa but not against 
Gram positive bacteria such as Staphylococcus aureus. 
 HBD-3 is induced by contact with tumor necrosis factor-α and 
certain pathogens. It has potent antimicrobial activity against 
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Staphylococcus aureus and vancomycin-resistant Enterococcus faecium, 
making it the first human β -defensin in skin to be effective against Gram 
positive bacteria. 
Toll like receptors (TLRS):- 
TLRs occur on the cell membranes and recognize certain 
exogenous ligands that are unique to invading microorganisms and not 
found in the host. They play a prominent role as primary sensors for 
invading pathogens. TLR5 recognizes flagellin, unique to flagellated 
bacteria, and TLR2 recognizes the peptidoglycan on the surface of Gram 
positive bacteria. TLRS also instruct antigen presenting cells that have 
engaged the organism to secrete appropriate cytokines to generate the 
desired immunologic milieu and eventual adaptive immune response. 
Complement:- 
Mannan-binding lectin binds to carbohydrate patterns on bacteria 
and activates C2 and C4. Activation of C3 liberates C3a and C3b. C3b on 
membranes leads to opsonization and enhanced phagocytosis. The 
cleavage of C5 leads to C5a, a potent activator of neutrophils and a 
stimulator of pro-inflammatory cytokines, including interleukin l(IL-l) 
and IL-8. The "membrane attack complex" is formed by completion of 
the complement cascade and kills invading microbes
[I7]
. 
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Lipids:-    
The free fatty acids, linoleic and linolenic acids are inhibitory for 
Staphylococcus aureus. Sphingosine, glucosylceramides, and cis-6-
hexadeconic acid have been demonstrated to have antimicrobial activity 
against Staphylococcus aureus. 
Resident flora, particularly the lipophilic corynebacteria, release 
lipases and thus contribute to defense against Streptococcus pyogenes and 
Staphylococcus aureus by liberating fatty acids from triglycerides of 
sebum. The acid mantle thus created favours the growth of 
propionibacterium, which in turn produce propionic acid; which has 
relatively more antimicrobial activity against transient organisms than 
resident flora.
[21] 
Bacterial interference:- 
Bacterial interference is the suppressive effect of one bacterial 
species on the colonization by another, exerts a major influence on the 
overall composition of the skin flora. Normal skin is colonized with 
resident bacterial flora, usually Staphylococcus epidermidis, other 
coagulase negative staphylococci, corynebacteria and Propionibacterium 
acnes. These bacteria form a protective layer and prevent the adhesion 
and multiplication of potential pathogens by producing many inhibitory 
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products or by modifying skin secretion. Staphylococcus aureus, when 
applied on the skin does not survive long but when applied on skin 
pretreated with 70% ethanol, it colonizes indicating the effect of bacterial 
interference. Colonization of a site by one strain of bacteria interferes 
with subsequent colonization by another strain of bacteria, which may be 
due to competition for same nutrient or by production of antibiotics.
[17] 
Keratinocytes and other epidermal cells produce reactive oxygen 
species, which have potent inflammation inducing properties as well as 
immunomodulatory properties that act as an important host defense 
mechanism against microbial invasion.
[17] 
Desquamation of skin results in loss of the transient flora.
[17]  
Adaptive immune response in skin
[19,20] 
Dendritic antigen presenting cells in the epidermis and dermis 
initiates adaptive immune response in skin while T lymphocytes and 
antibodies execute it. 
In skin, humoral immunity contributes to the immune defense 
against extracellular pathogens. Antibodies bind to microbial agents and 
neutralize them or facilitate uptake of the pathogen by phagocytes that 
destroy them. T lymphocytes contribute to cell-mediated immunity 
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(CMI), required to eliminate intracellular pathogens, by releasing 
cytokines. 
SECONDARY BACTERIAL INFECTIONS IN  SKIN LESONS: 
Secondary infections can arise from the invasion of certain 
organisms from the external environment through the breaks in the skin. 
The dermatological lesions taken up in this study are  
AtopicDermatitis/AtopicEczema, Psoriasis,  Pemphigus and Chronic 
infected ulcers of Leprosy. 
 1.Atopic Dermatitis/Eczema: Eczema also called  as dermatitis 
which means inflammation of the skin. There are different types of 
eczema. The most common type is atopic eczema.It is more common in 
children and young adults
[21]
. 
Common signs and symptoms of atopic dermatitis (eczema) 
include: 
Red to brownish-gray colored cracked or scaly skin lesions, 
itching, which may be severe, small raised bumps, which may ooze fluid 
and  forms crusts over the lesions which then leads to thickening of the 
skin Lesions of a topic dermatitis most commonly occurs in the folds of 
the elbows, backs of the knees or the front of the neck. It tends to flare 
periodically and then subside after a particular time
[22]
. 
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The presence of pustules, a purulent discharge,crusting combined 
with weeping crusting alone , or sudden appearance   of weeping, are 
taken as physical signs of infection
[24]
. 
In   eczema with secondary bacterial infection there is a typical 
pattern of skin inflammation which is  responsible for the  symptoms.  
The severity of the eczema and  Staphylococcus aureus colonization has 
been demonstrated, and it has been shown that bacterial colonization is an 
important factor aggravating skin lesions
[27]
. 
    In most patients with atopic dermatitis, even though there is an 
absence of skin lesions, colonization of Staphylococcus aureus will be 
noticed due to the altered immunological profile of atopic patients. 
Endogenous antimicrobial peptides i,e β-Defensins and Cathelicidines are 
under expressed in Atopic dermatitis. Clinical signs of impetiginization, 
such as weeping and crusting,  or small superficial pustules are all a  
sensitive indicator that indicates the numbers of Staphylococcus aureus 
may have increased and is a clinical indication of secondary infected 
dermatitis. But the recent research that has focussed on the role of 
Staphylococcus aureus in atopic dermatitis, offers a reversed perspective, 
by presenting evidence that the underlying pathology of atopic dermatitis, 
i.e. an alteration of the skin barrier and inflammation of the upper dermis, 
depends itself on the presence of an infectious process.  
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In other words, secondary infection with  Staphylococcus aureus 
emerging as a cause of atopic dermatitis. Recent research has greatly 
contributed to the understanding of the pathophysiological  role of 
Staphylococcus aureus superantigens in atopic dermatitis, suggesting that 
antibiotic therapy might be an important element in the therapeutic 
management of atopic dermatitis
[25,26]
. 
2. Psoriasis: 
It is a chronic lifelong skin disease most commonly causing 
erythematous papular and scaly plaques depending on lesion type. 
According to Gudionsson, E. J. et al. (2003); and Guo-li, et al. 
2009,
[98]
 Psoriasis is a chronic immunologically mediated inflammatory 
disease of the skin and joint, which has been found to affect 1-3% of 
population. The exact etiology is unknown, but researchers believe 
heredity, environment and immune system also play a role in psoriasis. 
Several  clinical types of disease have been identified but the 
chronic plaque form Psoriasis vulgaris is the most common type as per  
Gudion sson, E. J. et al. (2003). and Mallbris, L. et al. (2005). 
Psoriasis is a  T-lymphocyte mediated inflammatory skin disease 
considered to have an autoimmune etiology.  
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The link between psoriasis and infection is  most probably 
explained by the superantigen theory, that  is superantigens are the 
products of bacteria, viruses, or fungi, which can bypass normal 
immunological pathway and leads to powerful stimulation to the immune 
system.  According to Beaker B.S. et al. (2006)  M protein carried by 
Streptococcus pyogenes acts as superantigen in provoking psoriasis. 
Incidence of Psoriasis was found higher in in the age group of  (18-
40) years  and majority of them (48.7%) were showing  psoriatic lesions 
distributed whole over the body. Staphylococcus aureus is the most 
common cause of secondary infection (29.5%) followed by  Proteus spp. 
and Staphylococcus epidermidis . Others   like Pseudomonas aeruginosa, 
Bacillus spp are very rare
[27]
. 
3.Pemphigus: 
Pemphigus is an autoimmune intra epidermal blistering lesion of 
the skin and mucous membrane .The term is derived from Greek word 
pemphix for blister or bubble
[28,29]
. 
Pemphigus vulgaris    is the most common subtype of  pemphigus 
group of disorders, which presents as flaccid mucocutaneous blisters  and  
have a tendency to rupture easily followed by pemphigus foliaceus. 
 
 
18 
 
Pemphigus vulgaris (PV) and Pemphigus foliaceus (PF) are the 
organ-specific autoimmune bullous diseases characterized by loss of cell 
adhesion (acantholysis) and blister formation. These dermatoses are 
proved  to be induced by autoimmune phenomenon. Considering this 
etiology, immunosuppressive therapies are the mainstay in the treatments 
available for these disorders. Infections are important complications in 
these patients attributable to disruption of the epidermal barrier because 
of the disease itself and immunosuppression induced by treatment.  
There are many reports regarding predisposition to infections due 
to immunosuppressive therapy and the immunocompromised  state of  the 
pemphigus patients 
[33,34,35]
.    If left untreated, progression of the disease 
may lead to death within five years of the  onset , due to secondary 
bacterial infection and sepsis. 
Bullous pemphigoid is  another most common autoimmune 
blistering skin disease and presents with large, tense, cutaneous blisters. 
Rupture of  these bullae  produce erosions that are susceptible to bacterial 
infection
[30,31]
. 
The most common causes of mortality  in pemphigus are 
septicemia and pulmonary embolism; Septicemia usually follows 
cutaneous Staphylococcus aureus infection.  
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Before the advent of antibiotic therapy and  corticosteroids 
pemphigus vulgaris caused a substantial mortality.  Steroids, antibiotics 
and  immunosuppressive agents have drastically improved the 
prognosis
[36]
. 
4. Chronic infected ulcers of Leprosy 
Leprosy is a chronic infectious disease caused by the obligate 
intracellular pathogen Mycobacterium leprae . The bacteria grow best 
around 30⁰C  thus  have preference for the cooler areas of the human 
body
[37]
.  Leprosy remains a public health problem, mainly in Africa, 
Asia and Latin America
[38]
. 
Complications of Leprosy   are  leprosy reactions, development of 
plantar and palmar ulcerations, lagophthalomus (failure of eyelids 
function) and corneal anesthesia. Leprosy is not itself directly responsible 
for many of the complications. It impairs the sensation of pain and  hence  
exposes patients to ulceration and consequently to deformity. 
        Chronic ulcers are  the most serious complications of leprosy 
and these ulcers are highly infected with bacteria, which  is responsible 
for the delay in healing process. The delay is because of the competition 
between host cells and bacterial cells for oxygen and nutrients and also 
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the increased host cell production of inflammatory cytokines and 
proteases in response to the bacteria and their associated toxins. 
Pseudomonas aeruginosa is the most common   organism  
followed by staphylococci in Indian leprosy patients with ulcers
[42]
. 
There are absolute and relative indications   for  the use of 
antibiotics in leprosy ulcers. The absolute conditions   are  life threatening 
infective indications like septicemia and highly virulent bacterial 
infections such as staphylococci and streptococci. The relative  
indications  include the presence of complications like cellulitis, acute  
regional lymphadenopathy, systemic toxaemia and involvement of deeper 
structures like underlying bones, joints or tendon sheaths
[43,44]
. 
Diagnosis of Secondary Bacterial infections: 
 Diagnosis is by examining the clinical signs and symptoms of 
infection  followed by their culture and sensitivity.  Staphlococcus aureus 
is the most common cause of secondary infection in many lesions, 
followed by Enterobacteriacea  ,Group A beta haemolytic streptococci . 
Pathogenesis of staphylococcal infection: 
[45]
  
Virulence factors of Staphlococcus aureus: 
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Cell wall components: 
A.Capsule 
Decreases chemotaxis and phagocytosis, decreases proliferation of 
mononuclear cells,facilitates adherence to foreign bodies. 
B.Peptidoglycan 
Maintains osmotic stability,stimulates production of endogenous 
pyrogen (which have endotoxin like activity,leucocyte chemoattractant 
(abscess formation) and decreases phagocytosis. 
C.Teichoic acid 
 Regulates the cationic concentration at cell membrane and binds to 
fibronectin. 
D.Protein A 
Inhibits antibody mediated clearance by binding IgG1,IgG2 and 
IgG4 Fc receptors,leucocyte chemoattractants and anticomplementary. 
E.Cytoplasmic membrane: 
 It acts as an osmotic barrier,regulates transport in and out of the 
cells and is a site of biosynthetic and respiratory enzymes. 
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TOXINS: 
A.Cytotoxins:  α, β, γ, δ and Panton Valentine Leukocidin: These 
are toxic for many cells including leucocytes, erythrocytes, macrophages, 
platelets and fibroblasts. 
B.Exfoliative toxin (ETA ,ETB):Serine proteases which splits the 
intercellular bridges in the stratum granulosum of epidermis. 
C.Enterotoxins:(A-E,G-I) These are Superantigens that stimulates 
the proliferation of T-cells and release of cytokines and inflammatory 
mediators in the mast cells. 
D.Toxic Shock syndrome toxin I:Super antigen produce leakage 
and cellular destruction of endothelial cells 
Enzymes: 
A. Coagulase:Converts fibrinogen to fibrin. 
B. Catalase:Catalyzes removal of H2O2 . 
C. Hyaluronidase; Hydrolyzes hyaluronic acid in connective tissue, 
promoting the spread of staphylococci in tissue 
D. fibrinolysin:Dissolves fibrin clots 
E. Lipases: Hydrolyzes lipids 
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F. Nucleases:Hydrolyzes DNA 
G. Penicillinase:Hydrolyzes penicillin 
Role  of Staphylococcus  in Skin infections:
[19,46] 
For the effective invasion of the host ,the microbe must initially 
gain access. Staphylococcus aureus colonization may be transient or 
prolonged.Host Factors predisposing for staphylococcus infections are 
Atopy as in atopic dermatitis, Immunosuppression , preexisting tissue 
injury, and inflammation as in Pemphigus, Chronic ulcers of Leprosy and 
Psoriasis respectively. 
Staphylococcus utilizes teichoic acid and other surface proteins 
that promotes the adherence to nasal mucosa, which then contaminate the 
breaches in the skin. 
 It also secretes many specific substances that attack the 
components of innate immunity system of skin. 
Staphylokinase (SAK) inactivates defensins and activates 
plasminogen to plasmin. Surface plasmin cleaves C3b and 
immunoglobulin G, removing important opsonic molecules from bacterial 
surface. Chemotaxis inhibitory protein of Staphylococcus aureus binds to 
C5a,there by blocking neutrophil chemotaxis and activation. 
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Staphylococcal complement inhibitor binds to C3 convertase on the 
bacterial surface preventing it from C3 and complement cascade 
activation. 
Yellow pigment of Staphylococcus aureus(carotenoids)protect it 
from oxidative killing by neutrophils. 
Some strains produce one or more exotoxins like Staphylococcal 
enterotoxins,exfoliative toxins and leukocidin which inhibits the host 
immune response by their biological effect. Staphylococcal enterotoxin 
and TSS Toxin I acts as a super antigen,which produces massive  non 
specific T cell activation and release of cytokines like Interleukin 
1&2,interferonγ and Tumor necrosis factor α &β. Superantigen activation 
of T-cells also result in activation and expansion of lymphocytes 
expressing specific T cell receptor variable region of β chain.It may also 
activate B cells leading to high levels of IgE or autoantibodies. 
Mode of  infection: 
Moist skin of anterior nares of 20-40 % adults,intertrigenious skin 
folds,axilla,vagina and perineum of healthy person horbours 
Staphylococcus aureus. 
It may be exogenous, from direct contact, air borne or cross 
infection in hospitals or endogenous from colonization. 
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Diagnosis  of staphyloccal infection:
[47] 
Specimens include pus and exudates from infected lesions and 
Blood if there are signs of sepsis. 
Direct gram stain followed by culture, biochemical reactions and 
antibiotic sensitivity as per CLSI guidelines. 
Antimicrobial resistance in Staphylococcus aureus:  
Penicillin resistance:
 [48] 
Penicillin resistance has been increasingly recognized since 
1945.Nearly 80% or more strains of Staphylococcus aureus are resistant 
to penicillin.It is of 3 types. 
1. Plasmid mediated resistance:  
It is due to the production of the enzyme penicillinase (beta 
lactamase mediated by plasmids. The enzyme inactivates penicillin by 
splitting the beta lactam rings. Staphylococcus aureus produce 4 types of 
penicillinase (A, B, C, D). These plasmids are transmitted to 
Staphylococci by transduction and conjugation. The plasmid also carry 
resistance to other antibiotics like erythromycin and fusidic acid. 
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2. Chromosomal mediated resistance: 
Reduction in the affinity of penicillin binding protein  on the 
cellwall also  plays a role in mediating resistance to penicillin and other 
beta lactam antibiotics. 
3. Tolerance to penicillin: 
 Staphylococci developing tolerance to penicillin are only inhibited 
but not killed. 
Methicillin resistance: 
Methicillin resistance Staphylococcus aureus (MRSA) are resistant 
to all available penicillins and other beta lactam antibiotics. Resistance to  
methicillin indicates resistance to all cephalosporins. Many MRSA 
isolates are resistant to other antimicrobial families, including 
aminoglycosides, quinolones and macrolides. The first outbreak of 
MRSA infection occurred in European hospitals in 1960.From then there 
was a steady increase in occurance of MRSA infection and now it appears 
to be a worldwide phenomenon
[49]
. 
The prevalence of MRSA has shown an increasing trend in India.In 
1996, Pulimood from Vellore reported 24%
[50]
.The following year Udaya 
Shankar from Pondicherry reported 20%. 
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In 2006, Rajaduraipandi reported 37.9% from   Coimbatore
[50,51,52]
.   
A study conducted by  INSAR  group ,showed that the  prevalence of 
MRSA in our  country is about 40 %
[63]
. 
The source of MRSA may be community acquired or hospital 
acquired. The latter might be from infected patients or hospital staff. The 
CDC definition of community acquired MRSA (CA-MRSA)is any 
MRSA infection diagnosed from an out patient or within 48 hrs of 
hospitalization, if the  patient lacks the following healthcare associated 
risk factors, haemodialysis, surgery, long term hospitalization during 
previous year, presence of indwelling catheter or percutaneous device at 
the time of culture or previous isolation of MRSA from the patient. All 
others were considered to be hospital acquired MRSA(HA-MRSA)
[49]
. 
Mechanism of resistance 
Mediated by mecA gene which encodes for penicillin binding 
protein2a(PBP2a) that has low affinity for  beta lactams. mecA  is carried 
on a mobile genetic element The Staphylococcal cassette chromosome 
(SCCmec). 
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Five types of SCCmec have been reported 
Type I, II, III – HA – MRSA 
Type IV a-d and V, Panton Valentine leukocidin (PVL)- with    
subunits  lukS - PV  and  lukF PV – CA - MRSA. 
They are integrated in Staphylococcus aureus genome at3‟end of 
an open reading frame. 
The genetic difference  between HA-MRSA and CA-MRSA  is the 
presence of a bacteriophage (phiSLT) carrying the pvl gene in CA-
MRSA
[53]
. 
PVL is a bicomponent, pore forming leukotoxin initially called 
„substance leukocidine‟ by Van de Velde in 1894 because of its ability to 
lyse leuckocytes. Panton  and Valentine first associated the leukotoxin   
in 1932 before MRSA was of clinical concern with severe skin and soft 
tissue infections and necrotizing pneumonia among CA-MSSA and 
subsequently among CA-MRSA isolates 
[53]. 
The high virulence of CA-MRSA is associated with this PVL gene 
which mediate tissue necrosis and sepsis by either release of cytotoxic 
lysosomal granule contents from lysed  Polymorphonuclear leukocytes or 
by an inflammatory cascade or by apoptosis.PVL is associated with 
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epidemic CA-MRSA strains causing skin infections. Most CA-MRSA 
infections are skin and soft tissue infections.This epidemic has made  beta 
lactams which were previously uniformly effective against CA-MRSA 
isolates now becomes unreliable. 
Other mechanisms of methicillin resistance:- 
[91] 
Some strains of Staphylococcus aureus are not intrinsically 
resistant to methicillin and lack mecA and PBP2a. 
BORSA (Border line Resistant Staphylococcus aureus) are less 
susceptible to methicillin because of hyper production of normal 
penicillinase. 
MODSA (Methicillin Intermediate Staphylococcus aureus) show 
methicillin resistance due to other  mechanisms and have normal PBP. 
Both these groups are genetically distinct from MRSA and of 
unknown clinical and epidemiological importance though their infections 
can be effectively treated with beta lactamase resistant penicillins and 
cephalosporins. 
Detection and identification  of MRSA: 
MRSA can be detected by both phenotypic and genotypic 
methods,The ideal method for identification is by detection of mecA gene 
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or its product PBP2a. But because of the high cost and requirement of 
exepertise it is not performed in most clinical laboratories and phenotypic 
identification of intrinsic methicillin resistance is the standard method 
followed. 
A strain of Staphylococcus aureus is considered resistant to 
methicillin if the minimum inhibitory concentration(MIC) of oxacillin 
is≥4µg/ml[64].Oxacillin is preferred as it is more stable than methicillin. 
Methods of identification of MRSA:
[65] 
1. Screening methods: with cefoxitin / oxacillin disc by disc diffusion 
method. 
2. Confirmatory methods:  
Oxacillin MIC detection (by broth dilution, agar dilution, E test 
method),Oxacillin screen agar. 
3. Molecular methods: detection of Mec A gene or PBP2aprotein(its 
protein product). 
[66,67]
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Other methods are 
MRSA screen Latex tests, Evigene MRSA kit Chromogenic agar 
i) MRSA Select(Bipo-rad) 
ii) Chrome Agar MRSA(Bio connections). 
Typing methods for MRSA: 
1. Biotyping: 
It is a method to characterize  MRSA based on biochemical and 
morphological properties.[68].Based on the following 4 properties 
Tween 80 hydrolysis 
Pigment production on Tween 80 agar 
Urease production 
Gentamicin resistance 
Based on the result MRSA isolates have been divided into 4 
groups(A,B,C.D) 
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All MRSA isolates were classified into four biotypes in the 
following way: 
TEST 
                                            BIOTYPE 
A B C D 
Tween 80 
hydrolysis 
_ _ + + 
Urease _ + _ + 
Pigmentation Cream Buff Variable Gold 
Gentamycin 
resistance 
R R S R 
 
In India Biotyping by this technique was done for the first time in 
1993 by Krishna Prakash S and showed that majority belongs to group B. 
He  reported the same finding a decade later also.Similar finding were 
found by other author‟s also[69,70]. Since this technique is easy to perform 
,inexpensive and reproducible, in can be incorporated as a daily bench top 
procedure. 
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2. Antibiogram: 
MRSA can also be typed based on the susceptibility to a range of 
antibiotics. It is easy to perform but has a poor discriminatory ability and 
lacks reproducibility. 
3.Genotypic methods:
[66,67] 
Plasmid analysis 
Chromosomal DNA 
Restriction enzyme analysis 
Southern hybridization 
Ribotyping 
Coagulase gene typing 
Protein A gene typing 
RAPD 
Rep-PCR 
Mec-A:Tn 554 probe typing 
Pulse- field gel electrophoresis 
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Resistance to other antibiotics:  
Erythromycin and clindamycin: 
These two are two different classes of antimicrobial agents the 
inhibit protein synthesis by binding to 50S ribosomal unit of bacterial 
cell. In Staphylococci resistant to both these drugs occur through 
methylation of their ribosomal target site. Such resistance is mediated by 
the msr A. Another mechanism of resistance is by inactivation of 
lincosamides by chemical modification, which is mediated by inu A gene. 
The target site modification mechanism also called macrolide 
lincosamide-streptograminB(MLSB) resistance results in resistance to 
erythromycin, clindamycin and streptograminB.This may be constitutive 
or inducible. In constitutive rRNA methylase is always produced,whereas 
in inducible methylase is produced only in the presence of an inducer. 
Invitro, Staphylococcus aureus isolates with constitutive resistance 
are resistant to erythromycin and clindamycin and isolates with inducible 
resistance are resistant to erythromycin but appear susceptible to 
clindamycin and invivo therapy with  clindamycin  may select for  
constitutive erm mutants ,and leads to clinical failure. 
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Invitro induction test can distinguish  inducible erm –mediated 
resistance from those with msr-A mediated resistance.This is known as 
D-test
[71]
. 
Fluoroquinolones:  
Pefloxacin,ciprofloxacin and ofloxacin have activity   against 
Staphylococcus and can be considered for treatment.  The target of 
Fluoroquinolones in staphylococci is topoisomerase IV DNA gyrase.A 
point mutation in the grl A gene ,that encodes the A subunit of 
topoisomerase IV leads to resistance. Thus the major limitation of  
fluoroquinolones is that resistance develops easily  and hence have a 
limited role as monotherapy in serious infections
[72]
. 
Aminoglycosides: 
Gentamicin,netilmicin and tobramycin are the most effective 
aminoglycosides against Staphylococci. But not effective as a 
monotherapy  due to emergence of resistance. Plasmid mediated 
resistance develops against gentamicin
[72]
. 
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Vancomycin and Teicoplanin: 
These are glycopeptides active against MSSA and MRSA.  Mi – 
Na Kim et al (2000) reported a case of Vancomycin intermediate 
resistance in Staphylococcus aureus in Korea 
Mupirocin: 
It is a pseudomonic acid, a natural product of Pseudomonas 
fluorescens.It acts by inhibiting isoleucyl-tRNA snythetase in 
staphylococci.It is used topically to eradicate nasal carriage.Resistance 
develops due to the presence of an isoleucyl-tRNA synthetase gene 
located on a conjugative plasmid encoding gentamycin resistance.[72] 
Resistance in gram negative bacilli: 
a. Extended Spectrum Beta lactamases(ESBL) 
[56,57]
: 
These are Bush class A plasmid mediated beta lactamases capable 
of hydrolyzing  penicillins and monobactams and inhibited by beta 
lactamase inhibitors but have no  detectable activity against cephamycins 
or carbapenems and is produced mainly by members  of family 
Enterobacteriaceae,and also by some non fermentors.They also  carry 
resistance for other group of antibiotics(like aminoglycosides, 
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fluroquinolones, cotrimoxazole etc) which  narrow  down the choices of 
antibiotics available for  treatment. 
Detection methods for Extended Spectrum BetaLactamases :
[62] 
1. Screening methods: with cefotaxime/Ceftriaxone 
/cefpodoxime/ceftazidime aztreonam discs by disc diffusion 
method. 
2. CLSI phenotypic confirmatory methods:  broth microdilution 
method/disc diffusion method. 
3. Other methods: Inhibitor potentiated disc diffusion test,double disc 
diffusion synergy test,  ESBL Epsilometer test,automated methods. 
4. Molecular methods:PCR,DNA probes,PCR-RFLP,PCR-SSCP, 
Oligonucleotide sequencing. 
AmpC production in gram negative bacilli: 
Amp C beta lactamases are Bush class C beta lactamases(plasmid 
or chromosomal mediated), which  are resistant to all beta lactamases and 
also to beta lactamase inhibitor combinations. They are sensitive to 4th 
generation cephalosporins and to carbapenems. The main Amp C 
producing microbes were Acinetobacter species and Klebsiella species. 
 
 
38 
 
Detection methodsAmpC beta lactamases :
[59] 
1. Screening methods: with  cefoxitin disc by disc diffusion method, 
Cefoxitin agar method, Inhibitor based methods, AmpC disc test, 
Modified three dimensional test, Amp C beta lactamase  
Epsilometer  test. 
2. Molecular methods: PCR based methods 
c) Metallo beta lactamases in gram negative bacilli :
[60,61] 
MBL These  are Bush class C betalactamases capable of 
hydrolysing carbapenems,other beta lactams and beta lactamase inhibitors 
with the exception of aztreonam. They are predominantly found in 
Acinetobacter baumanii and Pseudomonas aeruginosa. 
Detection methods for MBL: 
1. Screening methods: with a carbapenemdisc (imipenem, 
meropenem, ertapenem etc) 
2. Confirmatory methods: Imipenem –EDTA combined disc method, 
Imipenem EDTA double disc synergy test(DDST),EDTA disc 
potentiation test, HODGE test, MBL Epsilometer test. 
3. Molecular methods: PCR techniques\ 
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Treatment of secondary bacterial infection in chronic skin lesions:
[10] 
Antimicrobial agents that provide coverage for S. aureus as well as 
Cefoxitin, the carbapenems and a penicillin plus a beta lactamase 
inhibitor also provide cover against members of the family 
Enterobacteriaceae. Aminoglycosides, fourth-generation cephalosporins 
and quinolones should also be added to the other agents when treating  
these infections as per the culture and sensitivity reports. 
Treatment for MRSA infection: 
Strains of MRSA differ in their degree of resistance to various 
antibiotics.  MRSA strains are usually multidrug resistant  and most of 
them are resistant to a number of antibiotics except Glycopeptide 
antibiotics, but however recently MRSA with reduced susceptibility to 
glycopeptides has been reported. 
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MATERIAL AND METHODS 
The present study on secondary bacterial infections associated with 
dermatological lesions and their antimicrobial susceptibility pattern was  
carried out in the Institute of Microbiology, Madras Medical College  in 
association with the department of  Dermatolgy, at the Rajiv Gandhi 
Government General Hospital, Chennai. 
Study design & period: 
Cross sectional study. One year (from   September    2013 to   
August    2014) 
Study population:  Total number of 200 patients attending the 
department of Dermatolgy , Rajiv Gandhi Government General Hospital, 
Chennai  were included  for the study. 
Ethical clearence: 
Before starting the study,approval was obtained from the 
Institutional Ethics Committee. Informed consent was obtained from all 
the in-patients and out patients who satisfied the inclusion criteria. 
Inclusion criteria: 
 Patients older than 18 years. 
 IP/OP patients with suppurative infections of skin lesions attending 
the Dermatology Department of RGGGH, Chennai 
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Exclusion criteria: 
Patients less than 18 years. 
Patients with non suppurative skin lesions. 
Patients with sexually transmitted lesions. 
Collection of data: 
Data were collected from patients who satisfied the inclusion 
criteria, using the  preformed structured questionnaire. Demographic 
details like name, age, sex, address, date of admission, clinical data like 
presenting complaints, personal history, past medical history,  
immunocompromised status,  physical examination findings and details 
of clinical diagnosis were collected. 
SAMPLE COLLECTION AND TRANSPORT 
Samples collected: 
1. Pus  
2. Blood 
1. Pus : 
Swabs:   Swabs were prepared by mounting sterile cotton wool on 
a stick which were introduced into test tubes and plugged. These swabs 
were sterilized in the hot air oven at 160°C for 1 hour. 
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The specimen  of  pus were collected aseptically  with the help of 
three sterile swabs one for direct gram stain for detecting  pus cells and 
microorganisms, second swab for aerobic culture and third swab for 
anaerobic culture. The swabs were taken from the leading edge of the 
wound and placed in a sterile test tube and transported to the laboratory. 
2.  Blood: 
Under  strict aseptic precautions, venepuncture site was cleaned 
with 70% alcohol and then with 2 % Povidone Iodine. The disinfectant 
was allowed to act for 1 minute and then  5ml of blood sample was 
collected with a sterile syringe  and  added into a sterile crew capped 
blood culture bottle containing 25 ml of sterile Brain Heart Infusion 
broth(BHI broth)  at the  bed side and transported immediately to the 
laboratory. 
Processing of sample: 
Direct Gram stain : Smear of the specimens were prepared by 
evenly spreading the swab on a new glass slide, air dried, heat  fixed and 
stained using Gram staining technique. The smear was examined for the 
presence or absence of bacteria, their gram reaction, morphology, 
arrangement and  pus cells. 
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Aerobic culture: Second swab was inoculated onto Blood 
agar(BA), Nutrient agar(NA) and MacConkey agar plate and were 
incubated at 37°C for 48 hours. If no growth was detected after 48 hours 
of incubation the culture was considered negative for aerobic bacterial 
growth. 
IDENTIFICATION OF ISOLATES:- 
All the isolates obtained from the pus samples were identified by 
standard bacteriological techniques. 
IDENTIFICATION OF BETA  HEMOLYTIC STREPTOCOCCI
[73]
: 
Organisms suspected to be Beta-hemolytic streptococci from their 
colonial appearance on the blood agar, were identified by Gram stain  and 
by bacitracin sensitivity. 
IDENTIFICATION OF GRAM NEGATIVE BACILLI
[74-76]
:- 
Colonies suspected to be of Gram negative bacilli from their 
colonial appearance on blood agar and MacConkey's agar were subjected 
to preliminary tests like Gram staining, hanging drop for motility, 
catalase and oxidase tests. Those that were Gram negative bacilli catalase 
positive  and  oxidase negative were  identified as members of 
Enterobacteriaceae. They were identified to the species level with the 
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help of biochemical tests like indole, methyl red, Voges Proskauer, 
citrate, urease and triple sugar iron agar (TSI) tests. Those that were 
Gram negative bacilli  catalase positive and oxidase positive, triple sugar  
with an alkaline slant and no change in butt, production of bright bluish-
green, red or brown diffusible pigment on Muller Hinton agar were 
identified as pseudomonas species. 
IDENTIFICATION OF STAPHYLOCOCCI COLONIES 
[77,79] 
Colonies of Staphylococcus aureus were identified by the 
following characteristics. 
Colony morphology on Nutrient agar:- 
Colonies were large (2-4 mm diameter), circular, convex, smooth, 
shiny opaque and easily emulsifiable with golden yellow pigment/ white/ 
yellow. 
Colony morphology on Blood agar:- 
 Colonies were 1-3 mm in diameter with a smooth glistening 
surface, an entire edge, smooth butryous consistency and an opaque 
pigmented appearance with a zone of hemolysis around them. 
Colony morphology on MacConkey's agar:- 
Colonies were pink and small to medium in size.  
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Gram staining:- 
The morphology of the organisms from suspected colonies was 
confirmed by examining the smears by using a   Gram's staining technique. 
Colonies showing Gram positive cocci in  clusters were selected for 
further  identification. 
Carbohydrate fermentation:- 
The suspected isolates were tested for aerobic and anaerobic 
utilization of mannitol. A loopful of bacterial culture was inoculated into 
peptone water containing 1% sugar and 0.2% bromothymol blue as 
indicator and then incubated overnight at 37°C. Change of colour of the 
medium from blue to yellow indicated fermentation of sugar. A small 
inverted durhams tube was inserted to each tube to detect gas. 
Coagulase test:- 
Human plasma was used for performing the coagulase test. This 
was obtained by centrifuging human blood, with added 0.1% EDTA, at 
2000 rpm for 10 minutes. 
Slide coagulase test:- 
One or two staphylococcal colonies were emulsified in a drop of 
saline on a clean microscopic slide. If the strain was not autoagglutinable, 
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then undiluted plasma was added to the suspension using a Pasteur 
pipette. The appearance of coarse clumping visible to the naked eye 
within 5-10 seconds was taken as positive. Positive and negative controls 
were put up, to check the proper reactivity of plasma. Absence of 
clumping or any reaction taking more than 10 secondss were taken as 
negative slide coagulase test. 
Tube  coagulase test:- 
1 in 6 dilution of the plasma was prepared in normal saline (0.85% 
NaCl) and 1 ml volume of it was distributed in small tubes. One - two 
staphylococcal colonies were inoculated and emulsified in the diluted 
plasma. Positive control and negative control was put up using 
Staphylococcus aureus ATCC 25923 and Staphylococcus epidermidis 
respectively. To rule out spontaneous clotting of plasma, a tube of 
uninoculated plasma was taken. The tubes were incubated at 37°C  for 
upto 4 hours and were observed at 1 hour, 2 hours and 4 hours by tilting 
the tubes through 90°. The tubes which showed any degree of clot 
formation were taken as positive. The tubes in which the plasma 
remained wholly liquid or showed flocculent or ropy precipitate were 
read as negative. The negative tubes were left at room temperature 
overnight and re-examined in the next day. 
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ANTIMICROBIAL SUSCEPTIBILITY TESTING
[78,80]
:- 
All the bacterial isolates obtained from the clinical samples of 
patients were tested for antimicrobial resistance pattern by using Kirby-
Bauer disc diffusion method. 
Antimicrobial susceptibility testing by  Kirby – Bauer Disc Diffusion 
method: 
Preparation of inoculums and Application of discs:- 
1. With a sterile bacteriological wire loop 3- 5 well isolated  identical 
colonies on an agar plate culture were touched and transferred  and 
emulsified in 3-4ml of sterile peptone water. 
2. Suspension of organism in growth medium was matched to a 0.5 
McFarland standards. 
3. Using a sterile cotton swab, the suspension was streaked evenly on 
to the surface of the  cation adjusted Mueller Hinton Agar  in three 
directions rotating  the plate approximately 60 °C to ensure even 
distribution. 
4. The surface of the inoculated agar was allowed to dry for 3 to 5 
minutes with the lid in place before adding the antibiotic discs. 
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5. Appropriate antimicrobial discs, five discs per plate of 90mm 
diameter were placed on the surface of the agar using sterile  
forceps. 
Incubation 
After overnight incubation at 37°C, the diameters of zone of 
inhibition were measured in mm with a ruled template. 
Quality control tests were done every week using the following 
standard ATCC control strains for testing the performance of media & 
drugs. 
Interpretation of Zone of inhibition diameters were done according 
to CLSI guidelines. 
ATCC control strains: 
 Staphylococcus aureus–ATCC 25923 
 Escherichia coli-ATCC 25922 
 Pseudomonas aeruginosa-ATCC 27853 
 Klebsiella pneumoniae (ESBL)-ATCC 700603 
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Panel of antibiotics included for testing antimicrobial sensitivity of 
Gram negativebacilli. 
Antibiotic 
 
Disc 
content 
 
Gram negative 
bacilli 
 
Diameter of Zone of inhibition in 
mm. 
Break points 
Sensitive Intermediate Resistant 
Amikacin 30μg  ≥ 17 15-16 ≤ 14 
Cefotaxime 
30μg 
 
Enterobacteriaceae ≥26 23-25 ≤22 
Acinetobacter ≥23 15-22 ≤14 
Ceftazidime 
30μg 
 
Enterobacteriaceae ≥21 18-20 ≤17 
P.aeruginosa& 
Acinetobacter sp. 
≥18 15-17 ≤14 
Cotrimoxazole 
 
1.25/ 
23.75μg 
 ≥16 11-15 ≤10 
Ciprofloxacin 5 μg  ≥21 18-20 ≤17 
Gentamicin 10μg  ≥15 13-14 ≤12 
Imipenem 10μg 
Enterobacteriaceae ≥23 20-22 ≤19 
P.aeruginosa ≥19 16-18 ≤15 
Acinetobacter ≥16 14-15 ≤13 
Piperacillin- 
Tazobactam 
100μg/10 
μg 
 
≥21 18-20 ≤17 
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The panel of antibiotics included in the antimicrobial sensitivity 
testing for Gram positive cocci were (Himedia), 
 
 
Antibiotics Disc content 
Zone of inhibition in mm 
Sensitive Intermediate Resistance 
Amikacin 30µg ≥17 15-16 ≤14 
Ciprofloxacin 5µg ≥21 16-20 ≤15 
Cotrimoxazole 1.25/23.75µg ≥16 11-15 ≤10 
Chloramphenicol 30µg ≥18 13-17 ≤12 
Penicillin 10units ≥29 - ≤28 
Erythromycin 15µg ≥23 14-22 ≤13 
Cefoxitin 30µg ≥22 - ≤21 
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METHODS FOR DETECTION OF MRSA
[78,79,80,81,90]
:- 
1. Cefoxitin disc method:-  
0.5 Mcfarland‟s suspension of test isolate and Staphylococcus 
aureus ATCC 25923 ( control) was lawn cultured on cation adjusted 
MHA plates separately. 30 μg cefoxitin disc was placed on the surface of 
lawn culture of both isolates  and incubated at 33–35 °C  in ambient air 
for 16–18 hours. 
Interpretation: As per CLSI guidelines  
Zone of inhibition-≥22mm-MSSA 
Zone of inhibition-≤21mm-MRSA 
MINIMUM INHIBITORY CONCENTRATION BY EPSILOMETER TEST  
(E-TEST)
[82]
:- 
All MRSA isolates were subjected to MIC estimation against 
oxacillin, by using E-test method (HI-MEDIA). 
The E-test   test strips  contains antimicrobial agent with a 
continuous exponential gradient of antibiotics from 0.016µg to 256 µg 
immobilized on porous paper material  and MIC values printed on both 
sides identically . 
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Procedure: 
The strains were inoculated into tubes containing 2ml of peptone 
water. The suspension was sreaked onto the Mueller Hinton Agar  with 
2% Nacl   to give a lawn culture. E-test strips were placed on the 
inoculated plates. The plates were incubated at 37°C for 24 hours  and 
reading was taken the next day. 
MIC of the drug was taken at the point where the ellipse intersects 
the MIC scale on  the strip. Control strain ATCC Staphylococcus aureus 
25923 were tested in parallel. 
Interpretation: As per CLSI guidelines  
MIC=≤2 µg/ml –sensitive 
MIC=≥4 µg/ml –resistant 
Minimum Inhibitory Concentration (MIC) for detecting Vancomycin  
resistance: 
1. Culture media: cation adjusted Mueller Hinton broth.(pH 7.2-7.4) 
2. Preparation of stock antibiotic solution: [83] 
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Antibiotic stock solution was  prepared using the formula 
1000  x  V  x  C  =   W 
  P 
Where P= potency of the antibiotic in relation to the base. 
 (For vancomycin, P= 950/1000 mg; Himedia) 
V = volume of the stock solution to be prepared (10ml) 
C =final concentration of the antibiotic solution (1024μg/ml) 
W = weight of the antibiotic to be dissolved in the volume V 
Scheme of preparing dilution of antibiotics 
Preparation of working  antibiotic solution: 
 Two rows of 11 sterile plugged test tubes were arranged in the 
racks. 
 In a sterile screw capped bottle, 8ml of broth containing the 
concentration of antibiotic (128 µg/ml) required for the first tube in 
each row from appropriate stock solution (1024 µg/ml)  was 
prepared. 
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 The contents of the above container were mixed thoroughly and 
using a sterile pipette, 1ml of the stock solution was transferred to 
first tubes in each row. 
 Using a fresh pipette, 4ml of MH broth was added to 4ml of the 
stock solution , mixed well and from this concentration, 1ml was 
transferred to the second tube in each row 
 The procedure was repeated  till the 11th tube 
 The first row of tubes were inoculated with test organism 
 The second row of tubes were inoculated with ATCC 
Staphylococcus aureus 25923. 
 1 ml of the antibiotic free broth was placed  in the last tube in each 
row  as growth control. 
 1 ml of antibiotic solution   were  kept  as sterility control. 
 Inoculum preparation for the test and ATCC control and 
incubation: 
 To 9.9 ml of MH broth in a sterile container , 0.1 ml of 0.5 
Mcfarland turbidity matched test organism was added and mixed 
well. 
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 Using 2 ml sterile syringe, 1 ml of the above inoculum was 
transferred to each antibiotic containing  tubes in the first row and 
also to the growth control tube. 
 Similarly ATCC control strain inoculum was prepared and  
transferred to the tubes in the second row. 
 These tubes were incubated at 37°C overnight. 
Observation &Interpretation: 
 The MIC of ATCC control strain were observed, they were within 
sensitive range, hence the test was considered to be valid. 
 The lowest concentration of the antibiotic in which there was  no 
visible growth was taken as the MIC of the drug  for the test 
organism. 
 Interpretation: 
MIC of vancomycin : 
≤ 2µg/ml –     Susceptible 
4-8µg/ml – Intermediate 
≥16µg/ml -   Resistant 
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MOLECULAR METHOD: 
DETECTION IN  OF mecA AND pvl GENES IN  MRSA   ISOLATES:- 
Polymerase chain reaction: 
All the  MRSA isolates  were subjected to PCR for the detection of  
methicillin resistant gene mecA  and Staphylococcal cassette chromosome IV pvl 
GENE in the CAMRSA
[102,103]. 
DNA extraction: 
MRSA colonies (5-10) were inoculated into nutrient broth and 
incubated overnight at 37ºC. 1.5ml of overnight broth culture was 
transferred into 1.5ml of centrifuge tube and centrifuged at 10,000 rpm 
for 3 minutes. Supernatant was decanted; excess medium was removed 
by gently tapping the tube on a paper towel. 
Procedure: 
 The pellet obtained was suspended in 200µl of PBS. 
 180µl of Lysozyme digestion buffer and 20µl of Lysozyme were 
added. 
 Above mixture was mixed well and incubated at 37 ºC for 15min. 
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 After incubation 200µl of Lysis buffer and 20µl of Proteinase K 
[10mg/ml] were added and incubated at 56ºC for 10min in 
waterbath. 
 Then 300µl of Isopropanol was added and mixed well. 
 The whole lysate was transferred into PureFast spin column and 
centrifuged at 10000rpm for 1min. 
 Flow through was discarded and 500µl of Wash buffer-1 was 
added and centrifuged at 10000rpm for 1min. 
 Flow through was discarded and 500µl of Wash buffer-2 was 
added and centrifuged at 10000rpm for 1min. Washing was 
repeated one more time. 
 Flow through was discarded and the column was centrifuged for 
additional 2 minutes to remove any residual ethanol. 
 The DNA was eluted by adding 100µl of Elution buffer and 
centrifuged for 1min. The eluted DNA was used as the template for 
PCR. 
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Primers [Designed by HELINI Biomolecules, Chennai] 
GENE PRIMER SEQUENCES 
AMPLICON 
SIZE 
mecA 
(F) 
5‟-GCAATCGCTAAAGAACTAAG-3‟ 
220bp 
(R) 5‟-GGGACCAACATAACCTAATA-3‟ 
pvl  
(F) 
5‟-GTAAAATGTCTGGACATGATCCA– 3‟ 
420bp 
(R) 5‟-CAACTGTATTGGATAGCAAAAGC-3‟ 
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PCR Procedure: 
Reactions were set up as follows; 
Components Quantity 
HELINI 2X PCR Master Mix 10μl 
Primer Mix 10pmoles/Reactions 5μl 
Genomic DNA 5μl 
Total volume 20μl 
 
All the components were mixed gently and placed into PCR 
machine and programmed it as follows, 
Cycle Number Denaturation Annealing Extension 
1 94ºC for 5 min - - 
35 94ºC for 30sec 58ºC for 30sec 72ºC for 30sec 
1 - - 72º C for 5 min 
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Agarose gel electrophoresis: 
1. 2% agarose gel was prepared with  2gm of agarose in 100ml of 1x 
TAE(Tris Acetate EDTA) buffer 
2. To each PCR vial 8μl 6X Gel loading dye was added and mixed. 
3. From each PCR vial15μl was loaded into the well. 
4. Then 100bp DNA ladder and appropriate controls were loaded  . 
5. Electrophoresis was run at 50V till the dye reached three fourth 
distance and the bands were observed using UV Transilluminator.   
Interpretation: 
The amplified PCR products and 100bp ladder DNA molecular 
markers were seen as bright fluorescent bands. A 220bp corresponds to 
mecA, 420bp corresponds to pvl gene. 
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DETECTION OF ß LACTAMASE ENZYME PRODUCTION IN 
GRAM NEGATIVE BACILLI: 
A) EXTENDED SPECTRUM ß-LACTAMASES (ESBL) DTECTION 
METHODS: 
ESBL‟s are classified under  Bush class A ß- lactamases which are 
capable of hydrolyzing penicillins – oxyiminocephalosporins and 
monobactams (Aztreonam) and inhibited by ß-lactamase inhibitors 
(clavulanic acid, sulbactum and tazobactum) but have no detectable 
activity against cephamycins or carbapenems (Imipenem, Meropenem).  
1. ESBL Screening method: [85] 
Isolates of gram negative bacilli showing the following resistance 
pattern were considered to be possible ESBL producing strains. 
Antibiotic 
Zone diameter for possible 
ESBL producing strain 
Ceftazidime(30µg) ≤22mm 
Cefotaxime(30µg) ≤27mm 
Ceftriaxone(30µg) ≤25mm 
Aztreonam(30µg) ≤27mm 
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2. Double Disk Diffusion Synergy Test: [83] 
In  this test discs of third generation cephalosporins and Augmentin 
[Amoxicilin and Clavulanic acid] (20µg/10µg) (Himedia)  were kept 
30mm apart from centre to centre on  a lawn culture of 0.5 Mcfarlands 
test lsolate on  Mueller Hinton agar (MHA)  A clear extension of the edge 
of the inhibition zone of cephalosporin towards Augmentin disc was 
interpreted as positive for ESBL production. 
3. Phenotypic Confirmatory Double Disk Test: (PCDDT) [84] 
To 5ml of peptone water, 3-5 colonies of isolates grown on a non 
selective  culture medium was added and incubated for 2-4 hrs at 35⁰ C 
and the  turbidity was matched with 0.5 Mcfarlands standard.The test was 
lawn cultured onto MHA plate(HiMedia,Mumbai).Ceftazidime(30μg) 
disc and Ceftazidime/Clavulanic acid disc (30μg/10μg) 
(Himedia,Mumbai) were placed on the surface of the plate and 
incubatedovernight at 35⁰ C. An   increase in zone diameter of ≥5mm for 
Ceftazidime tested in combination with Clavulanic acid versus its zone 
when tested alone confirmed  the ESBL producing organism. 
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AmpC β lctamases detection methods [87]: 
1)Screening method: 
A lawn culture of 0.5 Mcfarland suspension of test isolate was 
made on MHA plate. Ceftazidime (30μg) disc were placed adjacent to 
cefoxitin (30μg) disc at a distance of 20 mm from each other.After 
overnight incubation at 35
⁰
 C, isolates showing blunting of ceftazidime 
zone of inhibition adjacent to cefoxitin disc or showing reduced 
susceptibility to ceftazidime and cefoxitin were considered as screen 
positive. 
2) AmpC disc test
[ 88]
: 
On a MHA plate ,lawn culture of ATCC E.coli 25922 was 
prepared.On a 6mm sterile disc ,which was  moistened with sterile 
saline,several colonies of test organism were inoculated. The inoculated 
disc was then placed beside a cefoxitin disc (30μg) (almost touching) on 
the inoculated plate. After incubation, flattening or indentation of the 
cefoxitin inhibition zone in the vicinity of the test disc were considered as 
AmpC positive isolate. 
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C) Metallo β lactamase (MBL) detection methods[ 87]: 
1) Imipenem- EDTA disc method: 
       A 10μg imipenem disc (Hi Media) containing 750μg of EDTA 
solution was placed on the lawn culture of test isolate in MHA plate.After 
incubation,isolates which show zone diameter <14mm were considered 
MBL negative,whereas isolates which  show zone diameter >17mm were 
considered MBL positive isolates. 
2)Imipenem –EDTA combined disk test: 
       Imipenem (10 μg) and 10μg Imipenem disc containing 750μg 
of EDTA  solution,were placed on a lawn culture of test organism on 
MHA plate and incubated  overnight. If the increase in inhibition zone 
with Imipenem- EDTA disc is ≥7mm than  the Imipenem disc alone, it 
was considered MBL positive. 
Anaerobic culture: 
[86,89] 
For anaerobic culture  the specimens (i.e) pus swab, wound swabs 
were inoculated directly into thioglycollate broth and Robertson cooked 
meat broth(RCM)  and transported to the laboratory. 
(Thioglycollate broth was kept in boiling water bath for 10 minutes 
just before inoculation to drive out dissolved oxygen.) 
 
 
65 
 
Processing of specimen: 
Specimens were inoculated onto freshly prepared and adequately 
dried  selective anaerobic blood agar and Blood agar(BA) plates . 
Inoculated plates were placed in anaerobic jar with media facing 
upwards. Commercially available Gas-pak was cut open at one corner 
and placed inside the jar and the lid of the jar was closed immediately and 
kept for incubation for 72 hours at 37ºC.Always a plate inoculated with 
Pseudomonas was put in the jar which served as a control to check 
maintenance of anaerobiasis. 
Inoculated thioglycollate broth and Robertson cooked meat 
broth(RCM) was incubated at 37ºC aerobically for 48-72 hours.Then 
subculture was done onto BA and selective anaerobic blood agar  plates 
and placed inside an anaerobic jar for incubation. 
After appropriate period of incubation all primary as well as 
subculture plates were examined for evidence of growth.Colony 
morphology was noted. Smears were made and Gram‟s staining done to 
determine the cellular morphology.  
Colonies suggestive of anaerobes was subcultured onto 
RCM.Aerotolerance was checked by inoculating BA plates and 
incubating it aerobically at 37ºC. It was examined for any growth and if 
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there was no growth (aerotolerance negative) it was considered as 
obligate anaerobe.  
Blood Culture: 
The patient‟s blood sample were inoculated into Brain Heart 
Infusion (BHI) Broth  and incubated at 37°C aerobically and examined 
for turbidity at 24 and 48 hours. If turbidity or haemolysis was observed 
in BHI, subcultures were done onto Blood Agar and MacConkey Agar. 
These plates were incubated aerobically at 37°C for 24 hrs. Any growth 
observed was identified up to species level by colony morphology, Gram 
staining, catalase test, oxidase test, motility and biochemical reactions. 
Subcultures were done every third day for a period of 10 days and  a 
negative report was given if no growth was observed 
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RESULTS 
This cross sectional study was conducted in the Institute of 
Microbiology, Madras Medical College in association with the 
department of Dermatology, at the Rajiv Gandhi Government General 
Hospital, Chennai .       
 Total number of  200 patients with  skin lesions who satisfied the 
inclusion criteria were included in this study from  September   2013 to   
August    2014. 
TABLE 1: DISTRIBUTION OF CASES  ACCORDING TO SKIN 
LESIONS 
 
Skin Lesion Number of cases Percent 
Atopic Dermatitis/Eczema 63 31.5 
Leprosy with infected ulcer  23 11.5 
Pemphigus 62 31.0 
Psoriasis 52 26.0 
Total 200 100.0 
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Out of 200 samples 63, 62,52 and 23 samples were taken 
respectively  from patients with Atopic Dermatitis/Eczema, Pemphigus, 
Psoriasis and Leprosy with infected ulcer . 
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TABLE 2: ANALYSIS OF SEX DISTRIBUTION OF CASES IN 
SKIN LESIONS(n=200) 
SEX Skin Lesion Total 
 
Atopic 
Dermatitis/Eczema 
Leprosy 
with 
infected 
ulcer 
Pemphigus Psoriasis 
 
F 21(33.33%) 6(26.08%) 27(43.54%) 24(46.15%) 78(39%) 
M 42(66.67%) 17(73.92%) 35(56.46%) 28(53.85%) 122(61%) 
Total 63 23 62 52 200 
 
Out of 200 samples  122  samples were taken from male patients and 78 
from female patients. 
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 TABLE 3 : DISTRIBUTION OF OP AND IP CASES (n=200) 
S.no Skin Lesion IP Percentage OP Percentage 
1 Atopic Dermatitis/Eczema 22 11 41 20.5 
2 Leprosy with infected ulcer  10 5 13 6.5 
3 Pemphigus 54 27 8 4 
4 Psoriasis 28 14 24 12 
 Total 114 57 86 43 
 
 
Our study includes 114 IP patients (57%) and 86 OP patients 
(43%). 
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 TABLE 4: ANALYSIS OF AGE DISTRIBUTION OF CASES IN 
SKIN LESIONS 
 Skin Lesion Total 
AGE 
Atopic Dermatitis / 
Eczema(n=63) 
Leprosy with 
infected ulcer 
(n=23) 
Pemphigus 
(n=62) 
Psoriasis 
(n=52) 
 
18-27 
Years 
23(36.50%) 1(4.34%) 2(3.22%)  15 
27-37 
Years 
18(28.57%) 5(21.73%) 2(3.22%) 2(3.84%) 32 
38-47 
Years 
1812(19.04%) 4(17.39%) 7(11.29%) 14(26.92%) 43 
48-57 
Years 
4(6.04%) 6(26.08) 16(25.80%) 11(21.15%) 37 
58-67 
Years 
5(7.09%) 4(17.39%) 17(27.41%) 21(40.38%) 47 
68-77 
Years 
1(1.58%) 2(8.69%) 12(19.35%) 4(7.69%) 19 
78-87 
Years 
- 1(4.34%) 6(9.67%) - 7 
 63 23 62 52 200 
 
 
 
 
72 
 
 
 
 
Atopic dermatitis/Eczema was more common in younger age 
groups, Psoriasis and pemphigus were  more common in the old and 
middle age groups respectively. 
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Table: 5 DISTRIBUTION OF CULTURE RESULTS IN SKIN 
LESIONS 
S.No SKIN LESION 
Culture 
positive 
% 
Culture 
Negative 
% 
1 
Atopic 
Dermatitis/Eczema(n=63) 
59 93.7 4 6.3 
2 
Leprosy with infected ulcer 
(n=23) 
23 100 0 0 
3 Pemphigus(n=62) 58 93.5 4 6.5 
4 Psoriasis(n=52) 36 69.2 16 30.8 
 Total 176 88 24 12 
 
Among  the various skin lesions  the highest culture  positivity rate 
was found in Leprosy with infected ulcer followed by Atopic Dermatitis / 
Eczema, pemphigus and psoriasis the least. 
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TABLE 6 :ANALYSIS OF ORGANISMS ISOLATED FROM SKIN LESIONS:(n=212) 
S.No 
Aerobic Gram 
Positive 
Organism 
Number % 
Aerobic  Gram 
Negative 
organism 
Number % 
Anaerobic 
organism 
Number % 
1 
Staphylococcus 
aureus 
107 50.47 Escherichia coli 20 9.4 Bacteroides 2 0.94 
2 
Staphylococcus 
epidermidis 
10 4.71 
Klebsiella 
oxytoca 
12 5.6 Peptostreptococci 4 1.88 
3 
Streptococcus 
pyogenes 
10 4.71 
Klebsiella 
pneumoniae 
6 2.83    
4    
Pseudomonas 
aeruginosa 
29 13.68    
5    
Proteus 
vulgaris 
10 4.71   
 
 
6    
Proteus 
mirabilis 
2 0.94   
 
 
 Total 127 59.9  79 37.27  6 2.82 
Aerobic  gram positive organisms accounts for 59.9% followed by Aerobic gram negative 37.27% and anaerobic 
organisms 2.83%. Staphylococcus aureus was the most commonly isolated organism in this study (50.47%), followed 
by,enterobacteriacea(23.59%), Pseudomonas aeroginosa (13.68%)  and anaerobic organisms (2.83%). 
 
 
75 
 
TABLE 7: ANALYSIS OF  ORGANISMS ISOLATED FROM IP 
AND OP CASES: 
S.n
o 
IP OP 
Tota
l 
Organism Nos Organism Nos  
1 Staphylococcus 
aureus 
60 
(46.8%) 
Staphylococcus 
aureus 
47 
(55.95%) 
107 
2 Pseudomonas 
aeruginosa 
18(14.06
%) 
Pseudomonas 
aeruginosa 
11(13.09
%) 
29 
3 
Escherichia coli 
14(10.09
%) 
Escherichia coli 6(7.14%) 20 
4 Staphylococcus 
epidermidis 
6(4%) 
Staphylococcus 
epidermidis 
4(4.76%) 10 
5 Streptococcus 
pyogenes 
4(3.12%) 
Streptococcus 
pyogenes 
6(7.14%) 10 
6 Klebsiella 
oxytoca 
9(7%) 
Klebsiella 
oxytoca 
3(3.57%) 12 
7 Klebsiella 
pneumoniae 
5(3.9%) 
Klebsiella 
pneumonia 
1(1.19%) 6 
8 Peptostreptococ
ci 
3(2%) 
Peptostreptococ
ci 
1(1.19%) 4 
9 Proteus 
vulgaris 
6(4%) 
Proteus 
vulgaris 
4(4.76%) 10 
10 Proteus 
mirabilis 
1(0.78%) 
Proteus 
mirabilis 
1(1.19%) 2 
11 Bacteroides 2(1.56%) Bacteroides 0 2 
 
Total 
128 
(60.37%) 
 
84 
(39.62%) 
212 
Staphylococcus aureus was the most commonly isolated organisms 
in both IP and OP cases.Enteric gram negative bacilli were more in IP 
cases than in OP cases. 
 
 
76 
 
TABLE 8: ANALYSIS OF ORGANISMS ISOLATED FROM 
DIFFERENT ANATOMICAL SITES 
S.no
. 
ORGANISM 
SITE OF LESION 
UPPE
R 
LIMB 
LOWE
R LIMB 
TRUN
K 
HEAD&NEC
K 
1 
Staphylococcus 
aureus 
45 41 18 3 
2 
Pseudomonas 
aeruginosa 
4 19 2 4 
3 Escherichia coli 4 12 3 1 
4 
Staphylococcus 
epidermidis 
4 0 4 2 
5 
Streptococcus 
pyogenes 
6 2 2 0 
6 
Klebsiella 
oxytoca 
4 6 0 2 
7 
Klebsiella 
pneumoniae 
0 2 4 0 
8 
Peptostreptococc
i 
2 0 0 2 
9 Proteus vulgaris 2 8 0 0 
10 
Proteus 
mirabilis 
0 0 2 0 
11 Bacteroides 0 2 0 0 
Total 71 92 35 14 
Escherichia coli was  more commonly isolated from lower limbs 
than any other sites. 
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Anaerobic   Peptostreptococci were isolated from head and neck 
and Bacteroides from lower limbs.  
TABLE 9: DISTRIBUTION OF BACTERIAL ISOLATES  IN 
MIXED INFECTIONS IN SKIN LESIONS 
 
S.no Lesion Organism 1 Organism 2 
Number of mixed 
isolates 
1  
Atopic 
Dermatitis / 
Eczema 
(n=63) 
Staphylococcus 
aureus 
Peptostreptococci 2 
Staphylococcus 
aureus 
Klebsiella oxytoca 2 
Staphylococcus 
aureus 
Escherichia coli 2 
Staphylococcus 
aureus 
Bacteroids 2 
Total 8 (12.69%) 
2  
Leprosy with 
infected ulcer 
(n=23) 
Klebsiella oxytoca Escherichia coli 2 
Staphylococcus 
aureus 
Pseudomonas 2 
Total 4 (17.39%) 
3.  
 
 
 
Pemphigus 
(n=62) 
Pseudomonas Peptostreptococci 2 
Staphylococcus 
aureus 
Klebsiella pneumonia 1 
Staphylococcus 
aureus 
Klebsiella oxytoca 1 
Staphylococcus 
aureus 
Escherichia coli 2 
Staphylococcus 
aureus 
Pseudomonas 6 
Staphylococcus 
aureus 
Streptococcus 
pyogenes 
2 
CONS Pseudomonas 2 
Total 16 (25.80%) 
4.  
Psoriasis 
(n=52) 
Staphylococcus 
aureus 
Escherichia coli 2 
Staphylococcus 
aureus 
Proteus vulgaris 4 
Staphylococcus 
epidermidis 
Proteus mirabilis 2 
Total 8 (15.38%) 
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Mixed infections were found highest in Pemphigus(25.80%) 
followed by Leprosy with infected ulcer ,Psoriasis and Atopic 
Dermatitis/Eczema. 
TABLE 10: ANALYSIS OF ORGANISMS ISOLATED FROM 
PEMPHIGUS (n=74) 
S.no ORGANISM No Percentage 
1. Staphylococcus aureus 36 48.64 
2. Staphylococcus epidermidis 4 5.4 
3. Streptococcus pyogenes 2 2.7 
4. Pseudomonas aeruginosa 12 16.21 
5. Escherichia coli 8 10.81 
6. Klebsiella oxytoca 4 5.4 
7. Klebsiella pneumoniae 6 8.10 
8. Peptostreptococci 2 2.70 
Total 74  
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Staphylococcus aureus(48.64%)  were the most common organism 
in pemphigus  followed by Pseudomonas aeruginosa ,Enterobacteriaceae 
, Streptococcus pyogenes  and Anaerobic organisms. 
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TABLE 11: ANALYSIS OF ORGANISMS ISOLATED FROM   
ATOPIC DERMATITIS (n=67) 
S.No ORGANISM No % 
1. Staphylococcus aureus 41 61.19 
2. Streptococcus pyogenes 8 11.94 
3. Staphylococcus  
epidermidis 
4 5.97 
4. Escherichia coli 6 8.95 
5. Klebsiella oxytoca 4 5.97 
6. Peptostreptococci 2 2.98 
7. Bacteroides 2 2.98 
Total 67  
 
61.19% of isolates were Staphylococcus aureus followed by 
Streptococcus pyogenes,Enterobacteriacea and anaerobic organisms. 
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TABLE 12: ANALYSIS OF ORGANISMS ISOLATED FROM 
PSORIASIS(n=44) 
 
 
S.No ORGANISM No % 
1. Staphylococcus aureus 28 63.63 
2 Staphylococcus epidermidis  2 4.54 
3. Pseudomonas aeruginosa 4 (9.09 
4. Escherichia coli 4 9.09 
5. Proteus vulgaris 4 9.09 
6. Proteus mirabilis 2 4.54 
Total 44  
Most common isolate in Psoriasis was Staphylococcus aureus 
(63.3%) followed by Enterobacteriacea and Staphylococcus epidermidis. 
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TABLE 13: ANALYSIS OF ORGANISMS ISOLATED FROM 
LEPROSY WITH INFECTED ULCER 
S.No ORGANISM No % 
1. Pseudomonas aeruginosa 13 48.1 
2. Proteus vulgaris 6 22.2 
3. Staphylococcus aureus 2 7.4 
4. Klebsiella oxytoca 4 14.8 
5. Escherichia coli 2 7.4 
Total 27  
 
 
 
Pseudomonas aeruginosa (48%) was the most common organism 
in Leprosy with infected ulcer followed by Proteus vulgaris(22%). 
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TABLE 14 : ANALYSIS OF BLOOD CULTURE RESULTS: 
S.N
o 
Skin lesion                         BLOOD CULTURE 
POSITIV
E 
ORGANIS
M 
NEGATIV
E 
TOTA
L 
1 Pemphigus(n=6
2) 
2(3.22%) MRSA 9 11 
2 Psoriasis(n=52) 0 - 6 6 
 
Blood culture were taken for the patients with clinical signs of 
sepsis like fever.  
All of them were Inpatients. 
Two cases of pemphigus patients were positive for  culture. 
(3.22%) 
Methicillin resistant Staphylococcus aureus was isolated from both 
the patients. 
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TABLE 15 :ANTIBIOTIC SENSITIVITY PATTERN OF GRAM POSITIVE ORGANISMS 
S.n
o 
ORGANISM 
Tota
l no 
 
Amikacin Ciprofloxaci
n 
Cotrimoxazol
e 
Chloramphenic
ol 
Penicilli
n 
Erythromyci
n 
S % S % S % S % S % S % 
 
1 
 
Staphylococcu
s aureus 
107 
 
84 
 
78.5 
 
52 
 
48.6 
 
39 
 
36.4 - - 
 
39 
 
36.4 
 
41 
 
38.3 
 
2 
 
Staphylococcu
s epidermidis 
 
10 
 
9 
 
90 
 
6 
 
60 
 
4 
 
40 - - 
 
6 
 
60 
 
9 
 
90 
 
3 
 
Streptococcus 
Pyogenes 
 
10 
 
8 
 
80 
 
8 
 
80 0  
 
7 
 
70 
 
10 
 
100 
 
7 
 
70 
All gram positive organisms were highly sensitive to amikacin  and least sensitive to penicillin and cotrimoxazole. 
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TABLE 16 : ANTIBIOTIC SENSITIVITY PATTERN OF GRAM NEGATIVE BACILLI 
S.NO Antibiotic 
Escherichia 
coli  
(n = 20) 
Klebsiella 
oxytoca 
(n = 12) 
Klebsiella 
pneumonia 
(n = 6) 
Pseudomonas 
aeruginosa 
(n = 29) 
Proteus 
vulgaris 
(n = 10) 
Proteus 
mirabilis 
(n = 2) 
  S % S % S % S % S % S % 
1 Amikacin 17 85 7 58.3 4 66.7 22 75.9 7 70 1 50 
2 Cefotaxime 10 50 1 0.8 4 66.7 17 58.6 8 80 0 0 
3 Ceftazidime 10 50 1 0.8 4 66.7 17 58.6 8 80 0 0 
4 Cotrimoxazole 7 35 1 0.8 1 16.7 0 0 4 40 0 0 
4 Ciprofloxacin 7 35 0 0 2 33.3 12 41.4 0 0 0 0 
6 Gentamicin 14 70 2 1.6 2 33.3 13 44.8 2 20 0 0 
7 Imipenem 20 100 12 100 6 100 29 100 10 100 2 100 
8 
Piperacillin/ 
Tazobactum 
20 100 12 100 6 100 29 100 10 100 2 100 
S-sensitive 
All  gram negative bacilli were 100% sensitive to imipenem and piperacillin-tazobactum. 
All  gram negative isolates showed  higher rate of sensitivity to amikacin and least to ciprofloxacin 
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TABLE 17 :RESISTANT PATTERN IN GRAM NEGATIVE 
ORGANISM 
S.N
O 
ORGANIS
M 
TOTA
L NOS 
ESB
L 
DDS
T 
PCDD
T 
PERCENTAG
E 
1 Escherichia 
coli 
20 10 10 10 50 
2 Klebsiella 
oxytoca 
12 10 10 10 83.33 
3 Klebsiella 
pneumoniae 
6 3 3 3 50 
4 Proteus 
mirabilis 
2 2 2 2 100 
 Total 40 25 25 25 62.5 
DDST – Double disk diffusion synergy test 
PCDDT – Phenotypic Confirmatory disk diffusion test 
ESBL producers were 62.5%. All the ESBL producers  were sensitive to 
Imipenem. 
There was no Amp C ,and MBL producers in this study. 
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TABLE 18:  RESISTANT PATTERN OF STAPHYLOCOCCUS 
AUREUS 
 
 
Out of 107 Staphylococcus aureus 69(64%) were MSSAand 
38(36%) were MRSA. 
S.NO ORGANISM NOS PERCENTAGE 
1 MSSA 69 64.48 
 
2. 
 
MRSA  
CEFOXITIN 
DISC 
DIFFUSION 
38 35.52 
OXACILLIN 
E-TEST 
38 35.52 
 TOTAL  107  
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TABLE 19: Comparison of Antibiogram of MRSA AND MSSA 
S.N
o 
Staphyloco
ccus aureus 
Tot
al 
Amikaci
n 
Ciprofloxa
cin 
Cotrimoxaz
ole 
Penicilli
n 
Erythromy
cin 
S % S % S % S % S % 
1 MSSA 69 5
9 
85.
50 
43 62.3
2 
34 49.27 3
4 
49.
27 
37 53.
6 
2 MRSA 38 2
3 
60.
52 
8 21.1 8 21.05 4 10.
52 
7 18.
42 
3 P-value(by-
Pearson Chi-
Square test) 
  0.0
01 
 0.00
1 
 0.001  0.0
01 
0.0
01 
 
  S  S  S  S S  
S-Significant 
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     MRSA strains  were more resistant to all antimicrobial agents than 
MSSA and it was statistically significant. 
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TABLE 20:ISOLATION  OF mec A AND pvl GENES BY PCR IN 
MRSA 
S.No. GENE IP(n=18) OP(n=20) 
1 mec A 18(100%) 20(100%) 
2 Pvl 4(22.22%) 18(90%) 
3 mec A and pvl 4(22.22%) 18(90%)  
 
 
All MRSA were positive for mecA gene. 
MRSA from OP patients(CA MRSA) showed higher positivity for Pvl 
gene 90%  and  only 22% of MRSA from IP patients(HA MRSA) were 
positive for Pvl gene 
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TABLE21:INTERPRETATION OF MIC OF VANCOMYCIN FOR  
METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS  BY 
MACROBROTH DILUTION METHOD 
SKIN LESION no OF MRSA MIC value Interpretation 
Pemphigus 17 ≤ 2µg/ml Sensitive 
Atopic 
dermatitis/eczema 
13 ≤ 2µg/ml Sensitive 
Psoriasis 8 ≤ 2µg/ml Sensitive 
All the  Methicillin resistant  Staphylococcus aureus were sensitive 
to vancomycin. 
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DISCUSSION 
This cross sectional study was conducted in the Institute of 
Microbiology, Madras Medical College in association with the 
department of Dermatology , at the Rajiv Gandhi Government General 
Hospital, Chennai . 
Total number of  200  patients with  skin lesions who satisfied the 
inclusion criteria were included in this study. 
In this study  out of 200 samples, 63(31.5%) samples were taken 
from Atopic Dermatitis/Eczema cases, 62(31%) from Pemphigus , 
52(26%) Psoriasis and 23 (11.5%) samples were taken   from Leprosy 
with infected ulcer cases .(TABLE:1) 
Out of 200 samples 122 samples were taken from male patients and 
78 samples were taken from female patients. (TABLE 2).In cases  of 
leprosy with infected ulcer male cases were common. This was similar to 
the findings of Tsehayneshlema et al which explained  this predominance, 
as true difference between males and females and   is not because of the 
under diagnosis in women, due to delayed presentation of female patients, 
which results in high deformity . In all skin lesions male cases were more 
than the female cases. 
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114 (57%)   cases were  from In patients and 86(43%) cases were 
from out patients in this study(TABLE 3) 
Atopic Dermatitis cases were more common in the younger age 
groups in this study. (TABLE 4) J.Q. Gong et al 2006 and Wollenberg A 
Kraft S et al 2000 reported similar  age  distribution due to the 
development of tolerance to the allergens as age advances
[25,26,27]
. 
Though Psoriasis can occur at any age ,it  was common in the age 
group of 30 -60 years in this study   which was   similar to the studies by  
Shehab A. Lafi et al 2010 
[27]
 and Abdullah, M.; et al. (2007)
[1]
. These 
findings disagree with the  findings of Hwerta, C. et al. 2007 
[92]
 and 
Zieve, d. et al.2008 in which higher rate of Psoriasis was reported in the 
age group of 18-40 years  where most of the cases were Guttate psoriasis 
that is more common in younger age group .  This discrepancy might be 
due to difference in the type of psoriasis cases included in this study most 
of which were Psoriasis vulgaris that are common in the older age 
group(40-60 years). 
Pemphigus cases were common between the age group of 40-70 
years in this study   and Leprosy with infected ulcer shows no significant 
age distribution. 
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In this study out of 200 cases organisms were isolated from 176 
cases (88%) and in 24 cases(12%) culture were negative(TABLE5).  
The positivity rates differs among the skin lesions. In Atopic 
Dermatitis/eczema 93.7% cases were culture positive which was similar 
to the study  by Lübbe J 2003
[26]
.  
69.2% of Psoriasis cases were culture positive in this study  which 
was similar to the study by Itzhak brook et al 2002
[10]
,  but differs from 
Shehab A. Lafi1 et al 2010 
[27]
, which showed a higher rate of 
isolation(88%).  
Endogenous antimicrobial peptides such as cathelicidins and β 
defensins are over expressed in Psoriatic skin which was the reason for 
the lower rate of  secondary infection than Atopic dermatitis in which 
these peptides are under expressed 
[93]
. 
In Pemphigus 93.5% of cases showed positive cultures which was 
in accordance with the studies by Nousari HC et al 1999 and various 
other studies
[32,33,34,36]
.
  
In Leprosy with infected ulcer all the patients showed positive 
culture which was similar to Tsehayneshlema et al 2012 
[44]
 [TABLE 6] 
Total  number of organisms isolated in this study were 212.  
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127(59.9%) were aerobic gram positive organisms in which 
Staphylococcus aureus were 107(50.47%) followed by Staphylococcus 
epidermidis10(4.71%) and Streptococcus pyogenes10(4.71%). 
Similarly, Brook I et al 2002 and Marwa Abdallah 2007
[3,1]
  
mentioned that Staphylococcus aureus  was the commonest organism 
causing secondary infection of skin lesions and represented , 43.5% and 
61.8% of all positive cultures respectively. This might be related to the 
inhibitory effect of serum exuding from damaged skin on linolenic acid. 
Linolenic acid is an essential free fatty acid normally present on intact 
skin, which is responsible for inhibition of Staphylococcus aureus 
colonization 
[95].
  
79(37.26%) were aerobic gram  negative  organisms in which 
enteric gram negative bacilli were 50(23.59%) followed by Pseudomonas 
aeruginosa29(13.67%). This was similar to the studies by Brook I et al 
2002 and Marwa Abdallah et al  2007
[3,1]
  where enteric gram negative 
bacilli was in the range between 17.3to24.7%  
6(2.83%) were anaerobic organisms with 4(1.88%) being Gram 
positive cocci and 2(0.94%) being Gram negative rods. This finding was 
similar to the findings of Abdallah et al  2007, Brook I et al 2002 , 
[1,3]
 
which reported (1.7-7.1%) . (TABLE 7) 
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Out of 212 isolates 128(60.37%) were from IP cases and 
84(39.62%) were from OP cases. Staphylococcus aureus was the most 
common organism isolated from both the cases and there was no 
significant difference  between the isolation rate of all organisms ,except 
for the gram negative enteric organisms which were significantly more in 
inpatients .This was similar to the findings in the study by Marwa 
Abdallah etal 2007
[1].
(TABLE 8). 
In this study Staphylococcus aureus, was the most prevalent 
aerobe, isolated from all body sites. Similar findings were noted in the 
study by Marwa Abdallah et al 2007 
[1]
 suggesting that this organism may 
induce purulent superinfection as well as enhance the inflammatory 
process by superantigen-mediated T-cell activation 
[95] 
.  
Enteric gram-negative bacilli and Bacteroides spp. were found 
most common in the leg lesions. The probable sources of these organisms 
might be from the rectum and vagina, where they normally reside 
[97]
. 
Streptococcus  pyogenes   were most commonly found in lesions of the  
upper limb. These organisms probably reached these sites from the oral 
cavity, where they were part of the normal flora 
[11]
 (TABLE 9). 
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 Mixed infections in Pemphigus were 25.80% in this study 
followed by Leprosy with infected ulcer (17.39%), Psoriasis(15.38%)  
and Atopic Dermatitis (12.69%) respectively. 
Marwa Abdallah 2007
[1]
   reported similarly between 15 to 30% 
mixed infections in various skin lesions. The higher rate of polymicrobial 
infections in Pemphigus  and Psoriasis lesions were attributed to  the 
potential for bacterial synergy  and  immunosuppressive drugs that are 
indispensible in the treatment of these patients
[10]
.This findings disagree 
with the findings from the studies by Brook I et al 2002 and various other 
studies which reported higher rates of mixed infections (30 to50%) 
[1,4,13]
. 
Brook I et al and several studies have documented the synergestic 
effect of mixtures of aerobic and anaerobic bacteria in skin  and soft 
tissue infections . Various hypotheses have been proposed to explain such 
microbial synergy. It may be the result of  loss  of  protection  from 
phagocytosis and intracellular killing , or lowering of oxidation-reduction 
potentials in host tissue 
[95,96]
 . (TABLE10) 
Staphylococcus aureus(48.64%)  were the most common organism 
in pemphigus  followed by Pseudomonas aeruginosa ,Enterobacteriaceae 
, Streptococcus pyogenes  and anaerobic organisms  in this study. This 
was similar to the findings of Marwa Abdallah et al 2007
[1]
 and Nafiseh 
Esmaili et al 2013
[1,13]
 .  Studies by Itzhak brook et al 2002 and various 
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studies showed different pattern of infection in which Enterobacteriaceae 
was the second most common cause followed by Staphylococcus 
aureus
[3,33,35]
 .(TABLE 11) 
In this study61.19% of isolates from Atopic Dermatitis/Eczema 
were    Staphylococcus aureus followed by Streptococcus pyogenes ,    
Enterobacteriacea and anaerobic organisms. (TABLE12)This was 
similar to the studies by Marwa Abdallah  et al 2007 and Itzhak brook et 
al 2002[1,3]  which reported between60-90%.   This finding might be due 
to  the  higher colonisation of Staphylococcus aureus  in  atopic 
dermatitis patients  that might play a role in its pathogenesis.  
In this study most common isolate in Psoriasis was Staphylococcus 
aureus (63.63%) followed by Enterobacteriacea and Staphylococcus 
epidermidis.  
Staphylococcus aureus was predominant isolated bacteria from 
psoriatic patient lesions,( TABLE13) this was in agreement with  
Gudionsson, E. J. et al. 2003 and various other studies
[98,1,3,27]
 . 
Staphylococcus aureus was the commonest organism causing 
secondary infections of skin lesions, this might be attributed to the 
antiphagocytic effect of protein A of this organism, as well as the 
inhibitory effect of serum exuding from denuded skin on linolenic acid , 
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which is an essential fatty acid normally present on the intact skin  that 
helps in inhibiting Staphylococcus aureus colonization
[27]
. Isolation of 
opportunistic pathogens from psoriatic lesions , Staphylococcus 
epidermidis was due to the reduced local defense factors in the lesion due 
to local and systemic immunosuppressant drugs like cytotoxic drugs and 
corticosteroids used for the treatment of psoriasis
[27]
. 
 In this study Pseudomonas aeruginosa (48%) was the most 
common organism isolated from Leprosy with infected ulcer followed by 
Proteus vulgaris(22%),Klebsiella oxytoca, Staphylococcus aureus and 
Escherichia coli.( TABLE 14) 
This coincides with Srinivasan H et al 2004 and various other 
studies from India which showed the predominant isolate was 
Pseudomonas aeruginosa
[40,41,42,43]
. This findings disagree with the study 
by Tsehayneshlema et al 2012 
[44] 
in Ethiopia which showed Proteus as 
the predominant organism isolated.  
Blood cultures were done for the patient with clinical signs of 
sepsis like    fever. It was done for17 In patients [11 from 
Pemphigus(1.77%) and 6 from Psoriasis(1.15%)] .MRSA was isolated 
from two cases of Pemphigus. (TABLE 15) 
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This finding was different from the study by Ljubojevi´c et al on 
159 patients  done for a period of 19 years revealed that incidence of 
sepsis was about5.66%.This  low rate of sepsis in our study might be due 
to the small number of patients and the shorter period of our study. The 
severe complications were due to the high doses of corticosteroids and 
immunosuppressive therapy given to these patients.
[12]
 
A. Razzaque Ahmed et al 
[34]
 stated that Staphylococcus aureus was 
the commonest organism isolated from secondarily infected lesions of 
pemphigus  and the septicemia resulting from it was the most important 
cause of death. Hence, cautious observation and  antiseptic care for 
pemphigus lesions, along  with a judicious use of steroids is mandatory.  
All gram positive organisms were highly sensitive to amikacin (78-
90%) and least sensitive to cotrimoxazole and penicillin(36.4%).( 
TABLE 16) 
This finding differs from other studies by Marwa Abdallah  et al 2007 
and Itzhak brook et al 2002
[1,3]
 where they reported higher sensitivity rate 
for cotrimoxazole(60-78%) , which might be due to the use of different 
antibiotic regimen  in different settings. 
In this study all Gram negative organisms were 100% sensitive to 
imipenem and piperacillin-tazobactum, and higher rate of sensitivity to 
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amikacin and least sensitive to quinolones. This is similar to the findings 
of Marwa Abdallah  et al 2007
[1]
 (TABLE 17) 
ESBL producers in this study were 62.5%.[TABLE18].This was 
different from that of the study by Marwa Abdallah  et al 2007and 
various studies 
[1,13,36]
 which showed lower rates between 10-40%. 
All the organisms were sensitive to Imipenem and there were no 
AmpC or MBL producers in this study which was similar to that by S. 
Ljubojevi´c et al and Marwa Abdallah  et al 2007
[12,1].
 
36%of Staphylococcus aureus were Methicillin resistant in this 
study. (TABLE19)This correlates with the reports of various studies in 
India which ranges between20-40%. In 1996, Pulimood from Vellore 
reported 24%[50].The following year Udaya Shankar from Pondicherry 
reported 20%.In 2006, Rajaduraipandi reported 37.9% from 
Coimbatore.
[50,51,52] 
A study conducted by INSAR group ,showed that the 
prevalence of MRSA in our country is about 40 %.
[63]
 
All 38 isolates of MRSA were detected by cefoxitin disc diffusion 
and oxacillin MIC by E-test methods. This finding was similar to the 
studies by Mathew AA et al2010 and Anand KB et al 2009
[105,106]
 which 
showed 100%   sensitivity and  specificity in detecting mecA mediated 
MRSA by cefoxitin  disc diffusion method. 
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When comparing the antimicrobial susceptibility pattern of  MSSA 
and MRSA in this study MRSA isolates were found to be more resistant 
to the commonly used antibiotics than MSSA. Significant difference was 
observed in case of erythromycin, ciprofloxacin, cotrimoxazole, penicillin 
and amikacin.[P<0.05]. (TABLE:21)This was similar to the study 
conducted by INSAR group
[63]
 
All the MRSA isolates in this study were subjected to conventional   
PCR for the detection of methicillin resistant gene mecA  and pvl toxin 
gene. 
Out of 18 MRSA isolated from IP patients 18(100%) were positive 
for  mecA gene, 4 (22%)were positive for pvl gene and 4(22%) were 
positive for both . (TABLE21) Out of 20 MRSA isolated from OP 
patients,20(100%) were positive for mecA and 18(90%) were  positive 
for pvl gene. 
Similar to our study Binh An Diep et al 2004 and various studies 
reported  prevalence of pvl gene between 70 to 90% in the CA 
MRSA
[102,103,104,110]
. 
Binh An Diep et al 2004 described  that pvl gene along with the 
type IV SCC mec element contributes to the spread of MRSA in the 
community, particularly in the  skin and soft tissue infections. 
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22% of  MRSA from Inpatients also were positive for pvl gene 
which was similar to the study by Binh An Diep et al 2004  which  stated 
that the emergence of pvl type IV SCCmec MRSA strains in the 
community increases the concern that these strains would migrate into the 
hospital setting , and CA-MRSA strains which were susceptible to 
antibiotics other than the beta-lactams, would emerge  as a multi drug 
resistant strains
.[104,100,32]
 But our  findings were  in contrast to the studies 
by  D‟Souza N et  al 2010 and other studies  which showed 100% 
positivity of pvl gene in CA-MRSA and none of the HA-MRSA in these 
studies showed  pvl  gene
[107,108,109,]
. 
Susceptibility to Vancomycin was done by Macrobroth dilution     
method for all the MRSA isolates (TABLE22).All the isolates were found 
to be sensitive  which  was similar to the study by INSAR group
[63]
,which 
states that MRSA isolates were more resistant as compared with the 
MSSA isolates and  glycopeptides   continue to remain the mainstay for 
treatment for MRSA infections.  Hence   glycopeptides should be  
preserved  and encouraged to be used only in MRSA cases . 
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SUMMARY 
 A total of 200 patients with Secondary bacterial infection of 
dermatological lesions   were  analysed  during the one year study 
period. 
 Out of 200 samples 63(31%) , 62(31%),52(26%) and 23(12%) 
samples were taken respectively  from Atopic Dermatitis/Eczema, 
Pemphigus, Psoriasis and Leprosy with infected ulcer cases. 
 Out of  200  samples  122  samples were taken from male patients 
and 78 from female patients. 
 114 (57%)   cases were   from In patients and 86(43%) cases were 
from out patients. 
 Atopic dermatitis/Eczema was more common in younger age 
groups, Psoriasis and  pemphigus  were  more common in the old 
and middle age groups respectively. 
 88%   samples were culture   positive and 12 % were culture 
negative. 
 Among   the various skin lesions  the  highest culture  positivity 
rate was found in leprosy with infected ulcer(100%) followed by 
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Atopic Dermatitis/Eczema(93.7%) , pemphigus (93.5%) and 
psoriasis(69.2%) the least. 
 Aerobic Gram positive organisms accounts for 59.9% followed by 
aerobic gram negative 37.26% and anaerobic organisms 2.83%. 
 Staphylococcus aureus was the most commonly isolated organism 
in this study (50.47%), followed by enteric gram negative bacilli 
(23.59%), Pseudomonas aeruginosa (13.67%) and anaerobic 
organisms (2.83%). 
 Staphylococcus aureus was the most commonly isolated organisms 
in both IP and OP cases. Enteric gram negative bacilli were more 
in IP cases than in OP cases. 
 Escherichia coli  was  more commonly isolated from lower limbs. 
Anaerobic   Peptostreptococci were isolated from head and neck 
and      Bacteroides from lower limbs.  
 Mixed   infections  were found highest in Pemphigus(25.80%) 
followed by, Leprosy with infected ulcer(17.39%), 
Psoriasis(15.38%),Atopic Dermatitis/Eczema(12.69%) 
 Staphylococcus aureus(48.64%)  was the most common organism 
in pemphigus followed by Pseudomonas aeroginosa 
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,Enterobacteriaceae , Streptococcus pyogenes  and Anaerobic 
organisms. 
 In Atopic Dermatitis/Eczema 61.19% of isolates were 
Staphylococcus aureus followed by Streptococcus 
pyogenes,Enterobacteriacea and anaerobic organisms. 
 Most common isolate in Psoriasis was Staphylococcus aureus 
(63.63%) followed by Enteric gram negative bacilli and 
Staphylococcus epidermidis. 
 Pseudomonas aeruginosa (48.1%) was the most common organism 
in leprosy with infected ulcer followed by Proteus vulgaris 
(22.2%). 
 Blood culture from17 In patients, [11 from Pemphigus (1.77%) and 
6 from Psoriasis (1.15%)] resulted in MRSA isolation from two 
cases of Pemphigus. 
 All gram positive organisms were highly sensitive to amikacin  and  
least sensitive to penicillin and cotrimoxazole. 
 All   gram negative bacilli were 100% sensitive to imipenem and 
piperacillin-tazobactum and showed  higher rate of sensitivity to 
amikacin and least to ciprofloxacin. 
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 ESBL producers were 62.5%. All the ESBL producers  were 
sensitive to Imipenem. 
 Out of 107 Staphylococcus aureus 69(64.48%) were MSSA and 
38(35.52%) were MRSA. 
 MRSA strains were  resistant to most of the routinely used 
antimicrobial agents than MSSA. 
 All MRSA were positive for mecA gene.MRSA from OP 
patients(CA MRSA) showed higher positivity for Pvl gene 90%    
and   22% of MRSA from IP patients(HA MRSA) were positive 
for Pvl gene 
 All the  Methicillin resistant  Staphylococcus aureus were sensitive 
to vancomycin. 
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CONCLUSION 
  In this cross sectional study conducted at the Institute of  
Microbiology, Rajiv Gandhi Government General Hospital aimed at 
isolating the bacteria associated with dermatological lesions had revealed 
that Staphylococcus aureus was  the common pathogen in Atopic 
dermatitis/Eczema, Psoriasis,  Pemphigus lesions, from all body sites 
with nearly equal prevalence in inpatients and outpatients and 
Pseudomonas aeruginosa in chronic ulcers of leprosy patients. The 
incidence of Enterobacteriaceae infection was more in inpatients   with 
higher levels of ESBL production.CA MRSA and HA MRSA with higher 
rate of resistance to many routinely used antibiotics were isolated. 
 Hence bacterial culture and sensitivity of  specimens from the 
secondarily infected skin lesions should be performed to confirm the 
bacterial etiology and  to initiate effective  antibiotic treatment so as to 
decrease the morbidity and mortality of these patients, that  also limits the 
misuse of antimicrobials which would  prevent the emergence of resistant 
bacterial strains in the hospital and  the community.  
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APPENDIX – I 
ABBREVIATIONS 
SSTI - Skin and soft-tissue infection 
TLR - Toll-like receptor 
CMI  - Cell-mediated immunity  
PV - Pemphigus vulgaris  
PF - Pemphigus foliaceus 
 ET - Exfoliative toxin  
TSS - Toxic shock syndrome 
CLSI -  Clinical & Laboratory Standards Institute 
ATCC - American Type Culture Collections 
MIC - Minimum Inhibitory Concentration 
MRSA - Methicillin Resistant Staphylococcus aureus 
MSSA - Methicillin Sensitive staphylococcus aureus 
CA-MRSA - Community acquired Methicillin Resistant Staphylococcus 
aureus 
HA-MRSA  - Hospital acquired Methicillin Resistant Staphylococcus aureus 
SCC - Staphylococcal cassette chromosome 
PVL - Panton Valentine leukocidin  
PBP2a - Penicillin binding protein2a 
RAPD - Random Amplified Polymorphic DNA 
PCR - Polymerase chain reaction 
RFLP - Restriction fragment length polymorphism 
SSCP - Single strand conformation polymorphism 
PCDDT - Phenotypic Confirmatory Disk Diffusion Test 
DDST - Double Disc Synergy Test 
ESBL  - Extended Spectrum Beta Lactamase 
MBL - Metallo BetaLactamase 
IP - Inpatient 
OP - Out patient 
APPENDIX II 
A. STAINS AND REAGENTS 
1. Gram staining 
 
Methyl violet (2%) 
 
 
Grams Iodine  
Acetone  
Carbol fuchsin 1% 
l0g Methyl violet in 100ml absolute 
alcohol in 1 litre of distilled water 
(primary stain)  
l0g Iodine in 20g KI (fixative)  
Decolourising agent  
Secondary stain. 
B. MEDIA USED  
1. Mac Conkey agar 
Peptone 
Sodium taurocholate 
Distilled Water 
Agar 
2% neutral red in 50% ethanol 
10% lactose solution 
 
20g 
5 g 
1 ltr 
20 g 
3.5ml 
l00ml 
Dissolve peptone and taurocholate in water by heating. Add agar and dissolve 
it in steamer. Adjust pH to 7.5. Add lactose and neutral red shake well and mix.Heat 
in free steam (100°C) for 1 hour, then autoclave at 115°C for 15 minutes. 
2. Nutrient agar 
Peptic digest of animal tissue 5g 
Sodium chloride 5g 
Beef extract 1.5g 
Yeast extract 1.5g 
Agar 15gm 
Final pH 7.4±0.2  
Suspend 28 grams in 1000 ml distilled water. Heat to boiling to dissolve the 
medium completely and sterilized by autoclaving at 15 lbs pressure (120°C) for 15 
minutes.  
3. Blood agar (5% sheep blood agar) 
Peptone l0g 
NaCl 5g 
Distilled water 1 Ltr 
Agar l0g 
Dissolve ingredients in distilled water by boiling, and add 5% sheep 
blood(sterile) at 55°C adjust pH to 7.4. 
4. Chocolate agar 
Sterile defibrinated blood 10 ml 
Nutrient Agar (melted) 100 ml 
When the temperature was about 75°C, sterile blood was added with constant 
agitation. After addition of blood, kept in water bath and heating was continued till 
the blood changed to chocolate colour. Cooled to about 50° C and poured about 15ml 
into petri dishes with sterile precaution. 
5. Cation adjusted Mueller- Hinton Agar 
Beef infusion 300ml 
Caesein hydrolysate 17.5g 
Starch 1.5g 
Agar l0g 
Distilled water lltr  
pH = 7.4 
Sterilise by autoclaving at 121°C for 20 mins 
6.  Robertson's Cooked Meat Broth 
Fresh bullock heart 5 00g 
Water 500ml 
Sodium hydroxide, lmol/1 1.5ml 
Liquid filtered from cooked meat 500ml 
Peptone 2.5g 
NaCl 1.25g 
7. Selective Anaerobic Blood Agar: 
1 µg/ml menadione and 20 µg/ml gentamicin added to the blood agar. 
8. Thioglycollate broth 
Pancreatic digest of casein 15gms 
Yeast extract 5gms 
 Dextrose (Glucose)  5.5gms 
Sodium chloride 2.5gms 
L-Cystine 0.5gms 
 Autoclaved at 15 lbs pressure (121°C) for 20 minutes.  
Note: If more than the upper one-third of the medium has acquired a pink 
colour, the medium may be restored once by heating  in a water bath or  until the pink 
colour disappears. 
C. MEDIA REQUIRED FOR BIOCHEMICAL IDENTIFICATION 
1. Oxidase Reagent 
Tetra methyl p-phenylene diamine dihyrochloride- 1% aqueous solution. 
2. Catalase 
3% hydrogen peroxide 
3. Indole test 
Kovac's reagent 
Amyl or isoamyl alcohol 150ml Para dimethyl amino benzaldehyde lOg Concentrated 
hydrochloric acid 50ml 
Dissolve the aldehyde in the alcohol and slowly add the acid. Prepare in small quantities 
and store in the refrigerator. Shake gently before use. 
4.Christensen's Urease test medium 
Peptone lg 
Sodium chloride 5g 
Dipotassium hydrogen phosphate 2g 
Phenol red 6ml 
Agar 20g 
Distilled water 1 ltr 
10% sterile solution of glucose  10ml 
Sterile 20% urea solution  100ml 
Sterilize the glucose and urea solutions by filtration. Prepare the basal medium without 
glucose and urea, adjust to pH 6.8-6.9 and sterilize by autoclaving in a flask at 121°C for 30min. 
Cool to about 50°C, add the glucose & urea, and tube the medium as slopes. 
5. Simmon's Citrate Medium 
Koser's medium 1 ltr 
Agar 20 g 
Bromothymol blue 0.2% 40ml  
Dispense, autoclave at 121°C for 15 min and allow to set as slopes 
6. Triple Sugar Iron medium 
Beef extract  3g 
Yeast extract  3g 
Peptone  20g 
Glucose  lg 
Lactose  10 g 
Sucrose  l0g 
Ferric citrate  0.3g 
Sodium chloride  5g 
S odum thiosulphate  0.3g 
Agar  12g 
Phenol red 0.2% solution  12ml 
Distilled water  1 ltr 
 Heat to dissolve the solids, add the indicator solution, mix and tube. Sterilize at 121°C 
for 15 min and cool to form slopes with deep butts. 
7. Glucose phosphate broth 
Peptone 5g 
Dipotassium hydrogen phosphate 5g 
Water 1 ltr 
Glucose 10% solution 50ml 
 Dissolve the peptone and phosphate and adjust the pH to 7.6. Filter dispense in 5ml 
amounts and sterilize at 121°C for 15min. Sterilize the glucose solution by filtration and add 
0.25ml to each tube. 
Methyl Red Reagent 
Methyl Red  l0mg 
Ethyl alcohol  30ml 
Distilled water  20ml 
Voges Proskauer Reagent 
Reagent A: Alpha naphthol  5g 
Ethyl alcohol  100ml 
Reagent B: Potassium hydroxide  40g 
Distilled water  100ml 
8. Peptone water fermentation test medium 
 To the basal medium of peptone water, add sterilised sugars of 1% indicator 
bromothymol blue with Durham's tube. Basal medium peptone water Sugar solutions: 
Sugar  1ml 
Dislilled water  100ml  
pH = 7.6. 
9.  Mannitol motility medium 
Agar       5g 
Peptone     lg 
Potassium nitrate     1g 
Mannitol       2g 
Phenol red indicator 
Distilled water      1000ml  
pH        7.2 
10.  Phenolphthalein diphosphate agar 
 Sterilize a 1% aqueous solution of sodium phenolphthalein diphosphate by filtration and 
store at 4°C 
 Add 10ml of this solution to 1000ml melted nutrient agar cooled to 50°C and pour plates 
 Grow the staphylococcus overnight at 37°C on the medium 
 Invert the plate and pour a few drops of ammonia solution SG 0.88 into the lid 
 Read as positive a culture whose colonies turn bright pink within a few minutes. The 
colour soon fades. 
11.  Potassium nitrate broth 
Potassium nitrate (KNO3) 0.2gm 
Peptone 5.0gm 
Distilled water 100ml 
The above ingredients were mixed and transferred into tubes in 5 ml 
amount and autoclaved. 
12.  Phenyl alanine deaminase test 
Yeast Extract 3g 
Dl-Phenylalamine 2 g  
Disodium hydrogen phosphate l g  
Sodium Chloride 5 g  
Agar 12g 
Distilled water 1 lr 
PH 7.4 
Distributed in tubes and sterilized by autoclaving at 121° C for 1 5 minutes, 
allowed to solidify as long slopes. 
13. Sugar fermentation medium 
Peptone 15g 
Andrade's indicator 10 ml 
Sugar to be tested 20g 
Water 1 litre 
Andrade's indicator is prepared from 0.5% aqueous acid fuchsin to which 
sufficient 1M sodium hydroxide has been added to turn the colour of the solution 
yellow. 
Dissolve the peptone and Andrade's indicator in 1 litre of water and add 20g of 
the sugar; sugars to be tested generally include glucose, sucrose, lactose and maltose. 
Distribute 3ml amounts in standard test tubes containing an inverted Durham tube. 
Sterilize by steaming at 100 degree C for 30 min on 3 consecutive days. 
ANNEXURE-I 
 
 
ANNEXURE-II 
PROFORMA 
Name :      IP/OP No:______________________ 
Age : Ward:______________________      
Sex :  M / F 
Occupation: 
Address:_________________________________________________________ 
________________________________________________________________ 
Presenting complaints: 
 Skin lesions associated with pain and discharge 
Local examination: 
 Skin lesions with redness, swelling  
 Nature of discharge-purulent/watery 
Provisional diagnosis: 
Laboratory evaluation 
Microbiological investigation: 
Sample collected: 
• Swab from exudates of the lesion 
Direct examination 
Gram’s Stain: 
Bacterial Culture:  MAC 
BAP 
CAP 
Isolate identified in sample: 
 
Antibacterial susceptibility pattern: 
ANNEXURE-III 
CONSENT FORM 
STUDY TITLE: A study on secondary bacterial infections associated with 
dermatological lesions and their antimicrobial 
susceptibility pattern in a tertiary care hospital.” 
I…………………………………………, hereby give consent to 
participate in the study conducted by Dr.S.Vinotha, Post graduate at Institute of 
Microbiology, Madras Medical College, Chennai and to use my personal 
clinical data and the result of investigations for the purpose of analysis and to 
study the nature of the disease, I also give consent to give my  sample for 
further investigations. I also learn that there is no additional risk in this study. I 
also give my consent for my investigator to publish the data in any forum or 
journal. 
 
Signature/ Thumb impression of the patient/ relative 
Patient Name & Address: 
Place: 
Date: 
 
Signature of the investigator Signature of the guide: 
 
S.No Age Sex IP/OP No Wd Skin Lesion Site fever
Immuno
suppressants/
steroids
organism 1 organism 2 blood isolate Amikacin Cipro cotri chloramphenicol Penicillin erythro Cefoxitin Vancomycin Amikacin Cefotaxime Ceftazidime cotri Cipro Genta imipenem PT
1 72 M IP112824 44 Psoriasis Arm Y Staphylococcus aureus [MRSA] N N S R R R R R R S N N N N N N N N
2 72 F IP117921 45 Pemphigus Forearm Y Y Staphylococcus aureus N NG S S R R R R S N N N N N N N N N
3 74 M IP 118706 44 Atopic Dermatitis/Eczema Left Leg Y Escheria coli N N N N N N N N N N S S S R R S S S
4 22 M IP 114476 45 Atopic Dermatitis/Eczema Right Leg Y Staphylococcus aureus N N S S S S S S S N N N N N N N N N
5 57 M IP 112126 44 Psoriasis Right Hand Y Staphylococcus aureus [MRSA] Escheria coli N R R R R R R R S S S S S S S S S
6 60 M IP 120774 44 Atopic Dermatitis/Eczema Right Foot Y Staphylococcus aureus N N S R R S S S S N N N N N N N N N
7 56 M IP 120774 44 Psoriasis Left Hand Y Y Staphylococcus aureus proteus vulgaris NG S R S S R R S N S S S R R R S S
8 35 F IP121843 45 Pemphigus Forehead Scalp Y Y Staphylococcus aureus [MRSA] NG R R R R R R R S N N N N N N N N
9 55 M OP 777212 - Atopic Dermatitis/Eczema Right Arm N CONS[MS] N N S S S S R R S N N N N N N N N N
10 35 M OP 21382 - Atopic Dermatitis/Eczema Left Foot N Streptococcus pyogenes N N S R R S S S N N N N N N N N N N
11 53 F OP26864 - Atopic Dermatitis/Eczema Left Foot Y Staphylococcus aureus N N S R R S R R S N N N N N N N N N
12 35 M IP 110862 13  Leprosy  Right Arm Left Leg N Pseudomonas aeroginosa N N N N N N N N N N S S S R R R S S
13 84 F IP 6102 45 Pemphigus Back Y Y Staphylococcus aureus [MRSA] N
Staphylococcus 
aureus[MRSA] R R R R R R R S N N N N N N N N
14 20 M IP 130684 44 Pemphigus Back Y Staphylococcus aureus Klebsiella pneumoniae[ESBL] N S R S S S S S N S R R R R S S S
15 66 M IP27252 44 Pemphigus Left Leg Y Pseudomonas species N N N N N N N N N N S R R R R S S S
16 30 M IP26292 44 Psoriasis Scalp Y No Growth N N N N N N N N N N N N N N N N N N
17 52 M IP95234 44 Psoriasis Back Y CONS[MS] Proteus mirabilis [ESBL] N S S S S S S S N S R R R R R S S
18 60 F OP25670 - Atopic Dermatitis/Eczema Hand Y Streptococcus pyogenes N N S S R R S S N N N N N N N N N N
19 65 M OP21137  - Atopic Dermatitis/Eczema Right hand N CONS[MS] N N S R R S R S S N N N N N N N N N
20 62 M OP24848  - Atopic Dermatitis/Eczema Elbow back N Staphylococcus aureus Peptostreptococci N R S R S R R S N N N N N N N N N
21 48 M IP37962 44 Pemphigus Back Y Escheria coli[ESBL] N N N N N N N N N N S R R R R S S S
22 50 F IP37377 45 Pemphigus Scalp Y Pseudomonas species Peptostreptococci N N N N N N N N N S R R R R R S S
23 40 F IP38973 45 Pemphigus UL + Back Y Staphylococcus aureus Escheria coli[ESBL] N S S S S S S S N S R R R R S S S
24 65 F IP 33061 45 Pemphigus Left Arm Y Staphylococcus aureu N N S R R R R R S N N N N N N N N N
25 27 F IP40719 45 Pemphigus Left Leg Y Staphylococcus aureus N N S S S S S S S N N N N N N N N N
26 38 F IP33000 45 Psoriasis Back Y Pseudomonas aeroginosa N N N N N N N N N N S S S R S S S S
27 18 M IP41482 44 Atopic Dermatitis/Eczema Right Leg Y Staphylococcus aureus Bacteroids N S R R S R R S N N N N N N N N N
28 42 F IP36221 45 Psoriasis Left Leg Y Y Pseudomonas species N NG N N N N N N N N S S S R R R S S
29 42 F IP35670 45 Psoriasis Leg Y Escheria coli[ESBL] N N N N N N N N N N S R R S S S S S
30 38 F OP12186 Psoriasis Back Y Staphylococcus aureus N N S S S S R S S N N N N N N N N N
31 42 M OP21864 Atopic Dermatitis/Eczema Left Leg N Staphylococcus aureus Klebsiella oxytoca N S S S S S S S N S S S R R R S S
32 63 M OP31832 Pemphigus Back Y No Growth N N N N N N N N N N N N N N N N N N
33 23 M OP12186 Atopic Dermatitis/Eczema Right Hand N Streptococcus pyogenes N N S R R S S S N N N N N N N N N N
34 55 M IP110161 Psoriasis Right hand Y Staphylococcus aureus N N S R R S R R S N N N N N N N N N
35 68 M IP120614 44 Pemphigus Right Arm back Y Staphylococcus aureus Pseudomonas N S S S S S S S N R S S R S R S S
36 59 F IP110618 45 Psoriasis Scalp Y No Growth N N N N N N N N N N N N N N N N N N
37 42 F OP161721 Atopic Dermatitis/Eczema Left Leg N Staphylococcus aureus Escheria coli[ESBL] N S R R S R R S N S R R S S S S S
38 28 M IP11681 Atopic Dermatitis/Eczema Right foot N Staphylococcus aureus N N R R S S R R S N N N N N N N N N
39 59 M IP11863 Pemphigus Back Forehead Y Klebsiella oxytoca [ESBL] N N N N N N N N N N S R R R R S S S
40 28 F IP12823 Atopic Dermatitis/Eczema Right hand Y Staphylococcus aureus [MRSA] N N R R R R R R R S N N N N N N N N
41 42 F IP11682 Pemphigus Back Left Leg Y Y Escheria coli N NG N N N N N N N N S S S R R S S S
42 58 M IP110714 Pemphigus Right Leg Forehead Y Y Staphylococcus aureus[MRSA] N NG S R R S R R R S N N N N N N N N
43 63 F IP11191 Psoriasis Chest Y Y Staphylococcus aureus N NG R S R S S S S N N N N N N N N N
44 39 M OP31432 Psoriasis Left Hand Back Y No Growth N N N N N N N N N N N N N N N N N N
45 28 M OP31131  Leprosy  Right Arm Right Foot N Proteus vulgaris N N N N N N N N N N S S S R R R S S
46 34 M
HNO 98/14 
OP 32141  Leprosy  Right Arm Left Hand N Pseudomanas species N N N N N N N N N N R S S R S S S S
47 60 F OP41361 Psoriasis Buttock Y No Growth N N N N N N N N N N
48 41 M IP12361  Leprosy  Right Arm Right Arm N Klebsiella oxytoca [ESBL] N N N N N N N N N N R R R R R R S S
49 29 M IP120161 Atopic Dermatitis/Eczema Right hand Y Staphylococcus aureus N N S S R R R R S N N N N N N N N N
50 23 F
Lep. No.112/14 
O.P.30132 Leprosy with cellulitis Lt.leg Left Foot N Proteus vulgaris N N N N N N N N N N S S S R R R S S
51 32 M
H.No.56/14 
OP 31511 Leprosy bb Right Leg N Staphylococcus aureus Pseudomanas species N S R R R S S S N S R R R R R S S
52 50 M IP 130121 Pemphigus Right Leg Y Staphylococcus aureus N N S S S S S S S N N N N N N N N N
53 57 M IP64542 Psoriasis left leg Y Staphylococcus aureus Proteus vulgaris N R S R S R R S N R S S R R S S S
54 45 M OP52045 Atopic Dermatitis/Eczema Right foot N Staphylococcus aureus N N S S R S S R S N N N N N N N N N
55 60 F 65692 Psoriasis Left hand Y Staphylococcus aureus N N S R R R R R S N N N N N N N N N
56 65 F IP67600 Pemphigus Back Y CONS[MS] N N S R R S S S S N N N N N N N N N
57 47 F OP H.No.325/14  Leprosy  Right Arm Left leg N Pseudomanas species N N N N N N N N N N S R R R R R S S
58 50 M IP62146 Pemphigus Left leg Y Staphylococcus aureus Pseudomanas species N S R S S R S S N S S S R S S S S
59 13 M O.P 34088 Atopic Dermatitis/Eczema Right Arm N Staphylococcus aureus N N R R S S S S S N N N N N N N N N
60 53 M IP 68411 Pemphigus Back Y Staphylococcus aureus Streptococcus pyogenes N S S R S S S S N N N N N N N N N
61 25 M OP40812 Atopic Dermatitis/Eczema Right Hand N Staphylococcus aureus N N S S S S S S S N N N N N N N N N
62 45 M OP31087 Atopic Dermatitis/Eczema Left leg N Klebsiella oxytoca[ESBL] N N N N N N N N N N S R R S R R S S
63 28 F OP41812 Atopic Dermatitis/Eczema Right arm N No Growth N N N N N N N N N N N N N N N N N N
64 65 F IP63545 Psoriasis Back Y Staphylococcus aureus N N S S S S R R S N N N N N N N N N
65 70 F IP 51236 Pemphigus Left leg Y Y Escheria coli [ESBL] N N N N N N N N N N S R R R R R S S
66 50 M OP41713 Pemphigus Left leg Y Klebsiella pneumoniae N N N N N N N N N N R S S R R R S S
67 60 M OP31267 Psoriasis right forearm Y Staphylococcus aureus N N R R R S S S S N N N N N N N N N
68 48 M H.No.126/14  Leprosy  Right Arm Right leg N Proteus vulgaris N N N N N N N N N N S S S R R R S S
69 51 M H.No.113/13  Leprosy  Right Arm Left Foot N Pseudomonas N N N N N N N N N N S S S R S S S S
70 25 M OP51013 Atopic Dermatitis/Eczema Buttock N Escheria coli N N N N N N N N N N S S S S S S S S
71 38 M OP41715 Atopic Dermatitis/Eczema Righthand N Staphylococcus aureus[MRSA] N N S R R S R R R S N N N N N N N N
72 39 F IP43416 Pemphigus Righthand Y Staphylococcus aureus[MRSA] N N S R R R R R R S N N N N N N N N
73 40 F 51216 Psoriasis Right arm Y Staphylococcus aureus N N S R R S S S S N N N N N N N N N
74 29 F 51315 Atopic Dermatitis/Eczema Left arm N Staphylococcus aureus N N S S S S R R S N N N N N N N N N
75 65 F IP61234 Psoriasis Fore head Y No Growth N N N N N N N N N N N N N N N N N N
76 70 M IP51651 Pemphigus Left Leg Y Staphylococcus aureus Pseudomonas N S S R S R R S N N N N N N N N N
77 40 M IP112621 45 Pemphigus Back Y Staphylococcus aureus[MRSA] N N R R R R R R R S N N N N N N N N
78 38 M OP31267 Atopic Dermatitis/Eczema Right Hand N Staphylococcus aureus[MRSA] N N S R R R R R R S N N N N N N N N
79 43 M OP57313 Atopic Dermatitis/Eczema Left Arm N Staphylococcus aureus N N R S S S R S S N N N N N N N N N
80 65 M IP113217 Psoriasis Right Hand Y Staphylococcus aureus N N S S S S S S S N N N N N N N N N
81 35 F OP31337 Atopic Dermatitis/Eczema Right leg Y Staphylococcus aureus [MRSA] N N S S R S S R R S N N N N N N N N
82 68 F IP116532 Pemphigus Back Y Y Klebsiella pneumoniae [ESBL] N NG N N N N N N N N S R R R R S S S
83 56 F IP51321 Pemphigus Right Hand Y Staphylococcus aureus [MRSA] N N R R R S R R R S N N N N N N N N
84 60 F IP116113 Psoriasis Left leg Y Staphylococcus aureus N N R S S S R R S N N N N N N N N N
85 39 M OP32138 Atopic Dermatitis/Eczema Right hand N Streptococcus pyogenes N N S S R S S S N N N N N N N N N N
86 32 M OP41211 Atopic Dermatitis/Eczema Right arm N No Growth N N N N N N N N N N N N N N N N N N
87 68 M IP112812 Pemphigus Left leg Y No Growth N N N N N N N N N N N N N N N N N N
88 58 M Op 51312 Psoriasis Left hand Y No Growth N N N N N N N N N N N N N N N N N N
89 28 M OP31618 Atopic Dermatitis/Eczema Right leg N Staphylococcus aureus[MRSA] N N S R R S R R R S N N N N N N N N
90 40 F OP51218 Atopic Dermatitis/Eczema left thigh N Staphylococcus aureus N N S R R R S R S N N N N N N N N N
91 54 M IP116181 Pemphigus Back Y Staphylococcus aureus [MRSA] N N S S R S R R R S N N N N N N N N
92 48 M OP31241 Psoriasis Left leg Y No Growth N N N N N N N N N N N N N N N N N N
93 32 F OP21318 Atopic Dermatitis/Eczema Right leg N Staphylococcus aureus N N S S S S S S S N N N N N N N N N
94 40 F OP41216 Psoriasis Left hand Y No Growth N N N N N N N N N N N N N N N N N N
95 50 M Lep no221/13  Leprosy  Right Arm Right Hand N Klebsiella oxytoca[ESBL] Escheria coli N N N N N N N N N R/S R/S R/S R/S S/S S/S S/S S/S
96 80 F IP63646 Pemphigus Left leg Y Staphylococcus aureus N N S R R R R R S N N N N N N N N N
97 72 M IP61411 Psoriasis Right hand Y Staphylococcus aureus N N S R S S S R S N N N N N N N N N
98 62 F
Lep. No.106/13 
O.P.31816  Leprosy  Right Arm Right foot N Pseudomonas aeroginosa N N N N N N N N N N R R R R R R S S
99 80 M IP16122 Pemphigus Fore head Y CONS[MS] Pseudomonas N S R S S S S S N S S S S S S S S
100 69 F IP31244 Pemphigus Right leg Y Klebsiella oxytoca [ESBL] N N N N N N N N N N R R R R R R S S
101 82 M
Lep. No.126/13 
O.P.32114 Leprosy Left foot Left Foot N Pseudomonas N N N N N N N N N N S S S R S S S S
102 46 M
Lep. No.116/13 
O.P.12113  Leprosy  Right Arm Left Foot N Proteus vulgaris N N N N N N N N N N S S S S R R S S
103 61 F
Lep. No.131/13 
O.P.41236  Leprosy  Right Arm Right Leg N Staphylococcus aureus N N S S S S S S S N S R R R R R S S
104 46 F IP31621 Pemphigus Right Leg Y Staphylococcus aureus N N S S S S S S S N N N N N N N N N
105 53 M OP51617 Psoriasis left leg Y Y Staphylococcus aureus Proteus vulgaris NG S S R S R R S N R S S R R R S S
106 25 M IP63984 Atopic Dermatitis/Eczema Right foot Y Staphylococcus aureus N N R S S S R R S N N N N N N N N N
107 43 M IP41651 Psoriasis Left hand Y Staphylococcus aureus N N S R R R R R S N N N N N N N N N
108 69 F IP122621 Pemphigus Back Y CONS[MS] N N S S R R R S S N N N N N N N N N
109 49 M OP21267  Leprosy  Right Arm Left leg N Pseudomanas species N N N N N N N N N N S R S S S R S S
110 53 M OP56313 Pemphigus Left leg Y Staphylococcus aureus Pseudomanas species N S R R R S R S N S S S R S S S S
111 43 M IP112117 Atopic Dermatitis/Eczema Right Arm Y Staphylococcus aureus N N S S S S R S S N S S S S S S S S
112 66 F OP31427 Pemphigus Back N Staphylococcus aureus Streptococcus pyogenes S/S S/S S/R S/S R/S R/S S/N N/N N N N N N N N N
113 47 M IP116521 Psoriasis Right Hand Y Staphylococcus aureus [MRSA] N N S R R R R R R S N N N N N N N N
114 32 M IP51091 Atopic Dermatitis/Eczema Right leg Y Staphylococcus aureus N N S S S S S S S N N N N N N N N N
115 78 M IP112313 Pemphigus Back Y Klebsiella pneumoniae N N N N N N N N N N S S S S S S S S
116 55 M OP12138 Pemphigus Right Hand Y Staphylococcus aureus N N S S R S S S S N N N N N N N N N
117 71 M OP40611 Psoriasis Left leg Y Staphylococcus aureus N N S S R R R S S N N N N N N N N N
118 47 F IP101812 Atopic Dermatitis/Eczema Right hand Y Streptococcus pyogenes N N S R R S S R N N N N N N N N N N
119 33 M Op 31312 Atopic Dermatitis/Eczema Right arm N No Growth N N N N N N N N N N N N N N N N N N
120 42 M IP21973 Pemphigus Left leg Y No Growth N N N N N N N N N N N N N N N N N N
121 56 F IP 31061 Psoriasis Left hand Y No Growth N N N N N N N N N N N N N N N N N N
122 51 M IP40419 Atopic Dermatitis/Eczema Right leg N Staphylococcus aureus N N S S S S S S S N N N N N N N N N
123 62 F IP33042 Atopic Dermatitis/Eczema left thigh Y Staphylococcus aureus N N S S R R R R S N N N N N N N N N
124 67 M IP41422 Psoriasis Arm Y Staphylococcus aureus [MRSA] N N S R R R R R R S N N N N N N N N
125 66 M IP36311 Pemphigus Forearm Y Y Staphylococcus aureus N NG R R R R R R R S N N N N N N N N
126 32 M IP35661 Atopic Dermatitis/Eczema Left Leg Y Escheria coli N N N N N N N N N N S S S R R S S S
127 26 M OP12176 Atopic Dermatitis/Eczema Right Leg N Staphylococcus aureus N N S S S S S S S N N N N N N N N N
128 50 F OP21314 Psoriasis Right Hand Y Staphylococcus aureus [MRSA] Escheria coli N S R R R R R R S S S S R R S S S
129 29 M OP31830 Atopic Dermatitis/Eczema Right Foot N Staphylococcus aureus N N S S S S S S S N N N N N N N N N
130 47 M OP12176 Psoriasis Left Hand Y Y Staphylococcus aureus proteus vulgaris NG S S S S R S S N S S S R R S S S
131 52 M IP110123 Pemphigus Forehead Scalp Y Y Staphylococcus aureus [MRSA] N NG S S S S R R R S N N N N N N N N
132 42 F IP110614 Atopic Dermatitis/Eczema Right Arm Y CONS[MS] N N S R R S S S N N N N N N N N N N
133 34 F IP110718 Atopic Dermatitis/Eczema Left Foot Y Streptococcus pyogenes N N S S R S S S N N N N N N N N N N
134 65 F OP151721 Psoriasis Back Y Staphylococcus aureus [MRSA] N N R R R S R R R S N N N N N N N N
135 43 F IP11641 Atopic Dermatitis/Eczema Left Leg Y Staphylococcus aureus Klebsiella oxytoca [ESBL] N S S S S R S S N S R R R R R S S
136 49 F IP12863 Pemphigus Back Y No Growth N N N N N N N N N N N N N N N N N N
137 40 M IP12893 Atopic Dermatitis/Eczema Right Hand Y Streptococcus pyogenes N N S S R S S S N N N N N N N N N N
138 50 F IP11582 Psoriasis Right hand Y Staphylococcus aureus N N S R S S R R S N N N N N N N N N
139 56 F IP109714 Pemphigus Right Arm back Y Staphylococcus aureus [MRSA] Pseudomonas N S R S S R R R S R S S R S S S S
140 66 F IP111919 Psoriasis Scalp Y No Growth N N N N N N N N N N N N N N N N N N
141 33 M OP31222 Atopic Dermatitis/Eczema Left Leg N Staphylococcus aureus Escheria coli N S S R R R R S N S S S S S S S S
142 25 M OP31061 Atopic Dermatitis/Eczema Right foot N Staphylococcus aureus N N S S S S S S S N N N N N N N N N
143 47 M IP123211 Pemphigus Back Forehead Y Klebsiella oxytoca [ESBL] N N N N N N N N N N R R R R R R S S
144 34 M OP41231 Atopic Dermatitis/Eczema Right hand N Staphylococcus aureus [MRSA] N N S R R R R R R S N N N N N N N N
145 76 M IP143001 Pemphigus Back Y Staphylococcus aureus N N S S R S S R S N N N N N N N N N
146 56 F OP 51321 Psoriasis Left leg Y No Growth N N N N N N N N N N N N N N N N N N
147 23 F OP 32021 Atopic Dermatitis/Eczema Right leg N Staphylococcus aureus [MRSA] N N S S S S S S R S N N N N N N N N
148 45 M OP61231 Psoriasis Left hand N No Growth N N N N N N N N N N N N N N N N N N
149 66 M
Lep. No.86/13 
O.P.10013  Leprosy  Right Arm Right Hand N Klebsiella oxytoca[ESBL] Escheria coli N N N N N N N N S R/S R/S R/S S/S S/S S/S S/S S/S
150 69 F OP 67123 Pemphigus Left leg Y Staphylococcus aureus [MRSA] N N S R R S R R R S N N N N N N N N
151 60 F OP56712 Psoriasis Right hand Y Staphylococcus aureus [MRSA] N N S R R R R R R S N N N N N N N N
152 59 M
Lep. No.96/13 
O.P.10213  Leprosy  Right Arm Right foot N Pseudomonas aeroginosa N N N N N N N N N N R R R R R R S S
153 71 F IP110674 Pemphigus Fore head Y CONS (MS) Pseudomonas N S S R R R S S S S R R R R R S S
154 64 M IP210451 Pemphigus Right leg Y Klebsiella oxytoca [ESBL] N N N N N N N N N N S R R R R S S S
155 43 M OP31241 Atopic Dermatitis/Eczema Left Foot N Staphylococcus aureus[MRSA] N N S S S S R R R S N N N N N N N N
156 69 M
Lep. No.102/13 
O.P.10113  Leprosy  Right Arm Left Leg N Pseudomonas aeroginosa N N N N N N N N N N S R R R R R S S
157 58 F IP 456123 Pemphigus Back Y Y Staphylococcus aureus [MRSA] N Staphylococcus aureus[MRSA] S R R R R R R S N N N N N N N N
158 56 M IP116721 Pemphigous Vulgaris Back Y Staphylococcus aureus [MRSA] Klebsiella pneumoniae[ESBL] N S S R S R R R S S R R R R R S S
159 36 M IP 100237 Pemphigus Left Leg Y Pseudomonas species N N N N N N N N N N S R R R R S S S
160 66 F OP 32145 Psoriasis Scalp N No Growth N N N N N N N N N N N N N N N N N N
161 36 M OP 42131 Psoriasis Back N CONS[MS] Proteus mirabilis [ESBL] N S S S S S S S N R R R R R R S S
162 36 M OP21321 Atopic Dermatitis/Eczema Hand N Streptococcus pyogenes N N S S R S S S N N N N N N N N N N
163 29 M OP28291 Atopic Dermatitis/Eczema Right hand N CONS[MS] N N R S R S S S S N N N N N N N N N
164 34 M IP121109 Atopic Dermatitis/Eczema Elbow back Y Staphylococcus aureus [MRSA] Peptostreptococci N R S R S R R R S N N N N N N N N
165 46 F IP291231 Atopic Dermatitis/Eczema Buttock Y Escheria coli N N S S R S S R R S N N N N N N N N
166 44 F OP 31243 Atopic Dermatitis/Eczema Righthand N Staphylococcus aureus[MRSA] N N S R R R R R R S N N N N N N N N
167 48 F IP238761 Pemphigus Righthand Y Staphylococcus aureus[MRSA] N N R R R S S S S N N N N N N N N N
168 42 M OP21323 Psoriasis Right arm Y Staphylococcus aureus [MRSA] N N R R R R R R R S N N N N N N N N
169 25 M OP15642 Atopic Dermatitis/Eczema Left arm N Staphylococcus aureus[MRSA] N N S R R S R S R S N N N N N N N N
170 59 M IP 231212 Psoriasis Fore head Y No Growth N N N N N N N N N N N N N N N N N N
171 57 M IP211345 Pemphigus Left Leg Y Staphylococcus aureus Pseudomonas N S R R S R R S N S S S R R S S S
172 67 M OP21312 Pemphigus Back Y Staphylococcus aureus[MRSA] N N R R R R R R R S N N N N N N N N
173 37 F OP37869 Atopic Dermatitis/Eczema Right Hand N Staphylococcus aureus[MRSA] N N S S R R R R R S N N N N N N N N
174 23 F OP54321 Atopic Dermatitis/Eczema Left Arm N Staphylococcus aureus N N S S S S S S S N N N N N N N N N
175 66 F IP110987 Pemphigus Back Y Escheria coli N N N N N N N N N N S S S S S S S S
176 80 M IP132411 Bullous Pemphigoid Scalp Y Pseudomonas species Peptostreptococci N N N N N N N N N S S S R R R S S
177 79 M IP 123754 Pemphigus UL + Back Y Staphylococcus aureus Escheria coli N S S R R R R S N S S S R S S S S
178 58 M OP21321 Pemphigus Left Arm Y Staphylococcus aureus[MRSA] N N R R R R R R R S N N N N N N N N
179 61 M IP26754 Pemphigus Left Leg Y Staphylococcus aureus N N S S R R S S S N N N N N N N N N
180 59 M IP217611 Psoriasis Back Y Pseudomonas aeroginosa N N N N N N N N N N S S S R S S S S
181 45 M IP 100312 Atopic Dermatitis/Eczema Right Leg N Staphylococcus aureus Bacteroids N S S S S R R S N N N N N N N N N
182 58 F IP129810 Psoriasis Left Leg Y Y Pseudomonas species N NG N N N N N N N N R S S R R R S S
183 71 F OP 32785 Psoriasis Leg Y Escheria coli N N N N N N N N N N S S S S S S S S
184 48 F OP39870 Atopic Dermatitis/Eczema Right Hand N Staphylococcus aureus [MRSA] N N S R R S S S R S N N N N N N N N
185 34 F OP53421 Atopic Dermatitis/Eczema Left leg N Klebsiella oxytoca N N N N N N N N N N S S S R S R S S
186 33 M OP36712 Atopic Dermatitis/Eczema Right arm N No Growth N N N N N N N N N N N N N N N N N N
187 45 M OP29871 Psoriasis Back Y Staphylococcus aureus N N S R R S S S S N N N N N N N N N
188 69 M IP110981 Pemphigus Left leg Y Escheria coli[ESBL] N N N N N N N N N N S R R R R R S S
189 60 M IP217631 Pemphigus Left leg Y Klebsiella pneumoniae[ESBL] N N S S S S S S S N R S S R S R S S
190 58 M OP21312 Psoriasis right forearm Y Staphylococcus aureus N N S R R S S S S N N N N N N N N N
191 49 F
Lep. No.106/13 
O.P.11323  Leprosy  Right Arm Right leg N Proteus vulgaris N N N N N N N N N N R R R R R R S S
192 69 F
Lep. No.76/13 
O.P.10113  Leprosy  Right Arm Left Foot N Pseudomonas N N N N N N N N N N S S S R R R S S
193 60 F IP100932 Pemphigus Back Left Leg Y Escheria coli [ESBL] N N N N N N N N N N S R R R R R S S
194 59 F IP231321 Pemphigus Right Leg Forehead Y Staphylococcus aureus[MRSA] N N S R R R R R R S N N N N N N N N
195 66 M OP13423 Psoriasis Chest N Staphylococcus aureus N N S S S S S S S N N N N N N N N N
196 59 M OP34213 Psoriasis Left Hand Back Y No Growth N N N N N N N N N N N N N N N N N N
197 56 M
Lep. No.116/13 
O.P.12113
56/14
IP130981  Leprosy  Right Arm Right Foot N Proteus vulgaris N N N N N N N N N N S R R R R R S S
198 47 M
Lep. No.116/13 
O.P.12113  Leprosy  Right Arm Left Hand N Pseudomanas species N N N N N N N N N N S S S S S S S S
199 39 F OP321512 Psoriasis Buttock Y No Growth N N N N N N N N N N N N N N N N N N
200 36 M
Lep. No.116/13 
O.P.12113  Leprosy  Right Arm Right Arm N Klebsiella oxytoca[ESBL] N N N N N N N N N N S R R R R R S S
KEY TO MASTER CHART 
M Male 
F Female 
Y Yes 
N No 
Cipro Ciprofloxacin 
Cotri  Cotrimoxazole 
Erythro Erythromycin 
Genta Gentamicin 
PT Piperacillin-tazobactum 
R Resistant 
S Sensitive 
N Not done 
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